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1
I deFInItIon
clinical Pharmacology is the scientific discipline that 
involves all aspects of the relationship between 
drugs and humans. It is a multidisciplinary science 
that encompasses professionals with a wide variety 
of scientific skills including medicine, pharmacology, 
pharmacy, biomedical science and nursing. the 
term ’clinical pharmacologist’ is commonly used in 
the professional sense to refer to physicians who 
are specialists in clinical pharmacology. they have 
undertaken several years of postgraduate training 
in many aspects of the above relationship involving 
health care, teaching, and research. such clinical 
pharmacologists have as their primary goal that 
of improving patient care, directly or indirectly, by 
developing better medicines and promoting the safer 
and more effective use of drugs. 
I aIms
this document aims to set the scene for clinical 
pharmacology in the early part of the 21st century 
following the concepts of an earlier report by 
the world Health organisation in 1970 (1). this 
document is aimed primarily at decision makers in a 
variety of organisations, particularly in governments 
and their health care ministries, in addition to chief 
executives and board level directors of primary 
and secondary care systems and directors in 
pharmaceutical companies. It lays out in detail the 
great benefits that expertise in clinical pharmacology 
can bring to the delivery of better health care for all 
populations.
I  tHe clInIcal PHarmacologIst  
In PatIent care
clinical pharmacology has developed a number 
of ways in which the clinical care of patients can 
be improved (see chapter 6). the prime aim is to 
improve the rational Use of medicines both for 
individual patients and for patient populations 
wherever they may reside. clinical care of paediatric 
and geriatric patients needs special attention from 
the clinical pharmacologist and these special 
interests are addressed in chapters 7 and 8. the 
clinical pharmacologist is expert in the critical 
evaluation of new and old therapies, and uses drug 
utilisation studies and pharmacoepidemiological 
services to help in this task as well as skills such as 
pharmacogenetics. clinical pharmacologists have an 
important role on drug and therapeutics committees 
where they help the rational introduction and use 
of new and expensive medicines into the delivery 
of health care. clinical pharmacologists provide, in 
collaboration with other health care staff such as 
pharmacists, drug information services to a wide 
variety of prescribers. specialist services may include 
therapeutic drug monitoring, involvement in clinical 
drug toxicology and pharmacovigilance. adverse 
reactions to drugs still cause many problems for 
patients, and health care systems could do more 
to prevent these since most of them are predictable 
through a knowledge of pharmacology. 
the concept of personalised medicine is one where 
drug therapy can be based on the pharmacogenetic 
or other characteristics of a particular patient. while 
in its infancy as a discipline there are now good 
examples whereby adverse effects can be minimised 
and drug efficacy enhanced by a knowledge of 
the genetic makeup or other characteristics of the 
individual patient.
I  teacHIng clInIcal 
PHarmacologY
the teaching of clinical pharmacology is a vital 
part of the work of a clinical pharmacologist (see 
chapter 9 and addenda I and II). Perhaps the most 
important area is the training of new prescribers, 
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primarily medical students and new physicians. with 
the increasing trend for nurses and pharmacists to 
prescribe, usually in particular areas, attention needs 
to be paid also to their training in prescribing. the 
ability of new young physicians to prescribe safely 
and effectively has been criticised in recent years, 
and new systems are being developed to enhance 
these skills in the training of medical students. 
since assessment drives learning, the assessment 
systems are being improved too. specialist training 
of physician clinical pharmacologists is addressed in 
addendum II, since there is a world wide shortage of 
such specialists. However the needs, the resources, 
and the regulatory arrangements available in different 
countries mean that the approach suggested is a 
general one.
I  researcH domaIns oF clInIcal 
PHarmacologY
research is a vital part of the training and everyday 
work of a clinical pharmacologist (see chapter 10). 
the endeavour of a pharmacologist working in the 
clinical environment is to develop methods and 
strategies that improve the quality of drug use 
in individual patients and in patient populations. 
clinical pharmacological research has always 
been translational in the sense that the discipline 
aims to translate new scientific data on drugs into 
rational patient care. an increased engagement 
of clinical pharmacologists in the design, conduct 
and execution of clinical trials, particularly early 
phase I studies, would be advantageous. However, 
enhanced training in these areas may be required.
I  clInIcal PHarmacologY and 
tHe PHarmaceUtIcal IndUstrY
the pharmaceutical industry has been at the 
forefront of helping to train clinical pharmacologists 
(see chapter 12). while many of the skills acquired 
in such companies are useful for the general training 
of a clinical pharmacologist (e.g clinical trials) a long 
term career in such a company requires a new set of 
skills for which training and experience is needed.
I  goVernments: essentIal roles 
For clInIcal PHarmacologY
governments need clinical pharmacologists to help 
deliver the goal of ensuring safe and effective drug 
therapy for their populations, whether the clinical 
pharmacologists are working in hospitals, regulatory 
agencies or in Health technology assessment (Hta) 
(see chapter 13). with a few notable exceptions the 
discipline of Hta has emerged in the absence of 
contributions from clinical pharmacology. 
clinical pharmacologists have a crucial role to play 
in helping to deliver the wHo agenda of ”guidelines 
for the development of national drug Policies” to 
which more than 150 countries are now signed up 
(2). the policies aim to ensure:
• the quality, safety and efficacy of medicines
• equitable access to medicines for all the population
• the rational/quality use of medicines
•  a viable and responsible local pharmaceutical 
industry.
 
clinical pharmacologists are paying increasing 
attention to the health needs of those peoples who 
have in the past been marginalised. they include 
children, those with rare diseases, and those with 
conditions that are endemic in the poorest parts of 
the world. the training of clinical pharmacologists 
to meet these needs is rather different from that 
envisaged in 1970 when the first wHo report was 
published (1).
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some forty years ago the world Health organisation 
brought together a group of experts in clinical 
Pharmacology and therapeutics to define the 
discipline of clinical Pharmacology, and to outline 
how it could help to improve the use of drugs in the 
delivery of health care (1). In the last four decades 
the importance of drug therapy has changed 
markedly in terms of the potency of the drugs we 
use, in the number and diversity of drugs that are 
available, and in the number of diseases that can 
be treated. In addition the discipline of molecular 
biology has had an increasing impact on the 
development of drugs, but solid knowledge about 
the pharmacological principles that underpin the 
rational Use of medicines (rUm) is just as relevant 
now as it was in 1970.
since the production of the 1970 report the cost of 
developing drugs has risen substantially and the cost 
of taking a new chemical entity to market can easily 
be in excess of $Us 1000 million (£638 million, €764 
million). as a result newly developed drugs are very 
expensive, making it more difficult for resource poor 
countries to fund drug therapy for their inhabitants 
although there are welcome exceptions in the 
provision by Big Pharma of modern drugs at a very 
low or no cost (eg ivermectin for onchocerciasis). even 
resource rich countries have limitations in financing 
drug therapy and this has led to new concepts such 
as the cost effectiveness of drug therapy and to the 
discipline of pharmacoeconomics.
while clinical pharmacology is learning to face these 
new problems we are still dealing with problems in 
drug therapy that were recognised in the 1970s. we 
knew then that adverse reactions to drugs (adrs) 
were among the more common causes of admission 
to hospital (3) and this problem has not decreased 
in importance over the decades largely because little 
is done about it. In addition the problem of adrs 
is worsened by the increasing use of combination 
therapies and the higher proportion of elderly patients 
in the population. we know that adrs (the formal 
study of which has now given rise to the discipline 
of pharmacovigilance) cause some 7% of admissions 
to hospital and they are also a not uncommon 
cause of death, particularly in elderly patients (4,5). 
many of these adrs are predictable and could be 
prevented if the process of educating prescribers was 
taken more seriously. another problem that has not 
improved significantly over the years since 1970 is 
the errors made during the prescribing process in 
spite of the widespread availability of computers and 
the internet providing easy access to appropriate 
information and knowledge (6). these problems are 
more written about in resource rich countries but are 
just as relevant in resource-poor countries. 
It is clear then that the time has come to modernise the 
original wHo report in the light of lessons that have 
been learned and problems addressed. this updated 
report arises from a partnership between the world 
Health organisation (wHo), the International Union 
of Basic and clinical Pharmacology (IUPHar) and the 
council for International organizations of medical 
sciences (cIoms). after a period of expansion in 
the last 20 years of the twentieth century, clinical 
pharmacology as a discipline declined somewhat 
in many countries. However during the last few 
years there have been signs both of new growth 
in and new enthusiasm for the discipline (7), 
although the importance of clinical pharmacology 
to pharmaceutical companies has never been in 
doubt. a recent report on the relationship between 
the pharmaceutical industry and the national Health 
service (nHs in the United kingdom) has stated that 
re-building clinical pharmacology as a core discipline 
in the nHs is of vital importance for the future of 
health care in the Uk and this is likely to be true in 
many other countries (8).
Introduction 2
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this document aims to set the scene for clinical 
pharmacology in the early part of the 21st century 
by updating the concept of the original wHo report. 
we have gathered a group of distinguished clinical 
pharmacologists who have written the individual 
sections which are designed to address the essential 
role of clinical pharmacology in health care, teaching 
and research as well as describing the discipline’s 
link with industry and governments. we hope that 
the document will prove useful to many people, 
perhaps particularly young doctors who are looking 
to establish themselves in a clinical specialty and who 
have a particular interest in improving drug therapy 
and making it safer and more effective as exemplified 
in the wHo’s rational Use of medicines policy (9). 
However, this document is particularly aimed at 
decision makers in a variety of organisations, in 
governments and their health care ministries as 
well as chief executives and board level directors 
of primary and secondary care organisations 
and directors in the pharmaceutical industry. the 
document details the great benefits that expertise 
in clinical pharmacology can bring to the delivery of 
better health care for all populations. 
definition of clinical Pharmacology
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clinical Pharmacology is the scientific discipline that 
involves all aspects of the relationship between drugs 
and humans. Its breadth includes the discovery and 
development of new drugs, the application of drugs 
as therapeutic agents, the use of drugs, the beneficial 
and harmful effects of drugs in individuals and 
society, and the deliberate misuse of drugs. clinical 
pharmacology is a multidisciplinary team science 
that encompasses professionals with a wide variety 
of scientific skills including medicine, pharmacology, 
pharmacy, biomedical science and nursing. other 
professionals who are important in various aspects of 
clinical pharmacology include social and behavioural 
scientists, dentists, economists, epidemiologists, 
geneticists, toxicologists, mathematicians and 
computer scientists.
the descriptor ‘clinical pharmacologist’ is normally 
used in a professional sense to refer to physicians 
involved in the medical care of patients who are 
specialists in clinical pharmacology. they have 
usually undertaken several years of postgraduate 
training (see addendum II) focussing on important 
aspects of clinical pharmacology including clinical 
trials, drug evaluations, pharmacoepidemiology, 
pharmacoeconomics, pharmacovigilance and clinical 
drug toxicology. some countries have accreditation 
programmes for clinical pharmacology as a physician 
specialty but many do not. the present document 
refers essentially to medical clinical pharmacologists.
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History of clinical Pharmacology
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clinical pharmacology is both old and young. 
the practice of drug therapy goes back to ancient 
times and the discovery of drugs such as quinine, 
reserpine and artemisinin which were first used as 
herbal medicines. william withering’s publication on 
the use of foxglove in the treatment of heart failure 
(see10) may very well be considered the first scientific 
account of the discipline but it took 200 years 
before the pharmacology of digitalis was explored 
with accurate, clinical pharmacological methods. 
as a scientific discipline, clinical pharmacology is 
young having originated from the middle of the 
20th century. It is difficult to find who first coined 
the name as opinions differ between countries. 
several distinguished pharmacologists active in 
the middle of the century brought pharmacology 
and clinical know-how about drugs together and 
helped to transform drug evaluation from the trial 
and error state to a scientific discipline. In the anglo-
saxon literature, Harry gold at cornell (10,11) is 
commonly quoted as the person who first introduced 
the name clinical pharmacology in the early 1940s. 
However, in 1914, a textbook was written by Hans 
Horst meyer and rudolf gottlied in german the title 
of which was translated as ‘Pharmacology, clinical 
and experimental’. In addition, also in the german 
literature, Paul martini, professor of medicine in 
Bonn, published his monograph in 1932 entitled 
‘methodology of therapeutic Investigation’ and 
he is considered by some as the first clinical 
pharmacologist (12). according to shelley and Baur, 
his contributions escaped the attention of the english-
speaking world (12). In the english literature, there 
is a long tradition of ‘materia medica’, particularly 
in scotland. In 1884, John mitchell Bruce wrote his 
textbook entitled ‘materia medica and therapeutics. 
an Introduction to the rational treatment of disease’ 
and this, in its 20th edition, became dilling’s ‘clinical 
Pharmacology’. this book was published in 1960, 
the same year as desmond laurence’s textbook 
entitled ‘clinical Pharmacology’.
there is no doubt that the most vigorous attempts 
to develop clinical pharmacology as an academic 
discipline were made in the United states (13,14). 
Important landmarks are the first edition of 
goodman and gilman’s ‘the Pharmacological Basis 
of therapeutics’ and the successful attempt (1960) 
by walter modell, also at cornell, to launch the 
first scientific journal in the subject entitled ‘clinical 
Pharmacology and therapeutics’.
In the early 1960s, the United states became 
the world centre for the training of clinical 
pharmacologists. the nIH chief James shannon and 
his colleagues Bernard B. Brodie and Julius axelrod 
introduced biochemical pharmacology as a science 
and drug measurements in body fluids as tools in 
clinical pharmacology. several centres of excellence 
in clinical pharmacology offered training to potential 
clinical pharmacologists from all parts of the world. 
the efforts to improve clinical drug evaluation by 
louis lasagna, a pupil of Harry Beecher at John 
Hopkins Hospital, should be especially recognised 
(13,14). In1966, lasagna published a brilliant, 
still valid, account in science of the present status 
and future development of clinical pharmacology 
(14). the birth of clinical pharmacogenetics can be 
ascribed to the pioneering contributions of werner 
kalow and a.g. motulsky (15,16).
Parallel developments occurred in europe, particularly 
in the Uk, where the strong infrastructure in basic 
pharmacology and clinical medicine formed an 
excellent basis for a rapid growth of the discipline. 
names that are usually mentioned in this context 
are those of sir John gaddum, sir Horace smirk 
and sir austin Bradford Hill (10). chairs in clinical 
pharmacology were created at the end of the 1960s 
in germany, the Uk and sweden, although chairs 
in materia medica had long been established in 
scotland. academic growth of the discipline also took 
place in France (17). IUPHar took early initiatives to 
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develop clinical pharmacology. a section of clinical 
pharmacology was formed in the early 1970s and 
a division in the 1990s. several IUPHar executives 
strongly supported the discipline, particularly the 
first president Börje Uvnäs in sweden, but also sir 
arnold Burgen in the Uk and Helena raskova in 
czechoslovakia, who all realised that pharmacology 
had to reach out to the bedside in order to develop. 
wHo brought together a study group in 1970 (1) to 
write a report on the scope, organization and training 
of clinical pharmacology, led by the late sir derrick 
dunlop (Uk), and containing, amongst others, the 
late professors louis lasagna (Usa), Franz gross, 
(germany) and leon goldberg, (Usa). In 1991, wHo 
europe put together a booklet and a series of papers 
in the european Journal of clinical Pharmacology 
about the roles of clinical pharmacology in teaching, 
research and health care (18). For the first time, 
the potential usefulness of the discipline for the 
rUm in primary health care was emphasised. 
several nobel Prize laureates in medicine can 
be considered as representatives of clinical 
pharmacological research at its best such as sir John 
Vane, sir James Black, george Hitchings, gertrude 
elion and arvid carlsson. they all ‘practiced’ clinical 
pharmacology during their efforts to introduce 
new pharmacotherapeutic principles into clinical 
medicine.
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modern drug therapy has unquestionably 
transformed the health of peoples in developed 
countries over the last 50 years. conditions such as 
poliomyelitis, diphtheria and pertussis have largely 
been eliminated in wealthier nations. many lethal 
communicable diseases can be cured by modern 
antimicrobial agents. and complex surgery, beyond 
the imagination of our forefathers, can be performed 
safely and effectively using modern anaesthetic 
agents. those with chronic diseases have benefited 
immeasurably with the emergence of safe and 
effective treatments for asthma, hypertension and 
hypercholesterolaemia. 
nevertheless, there remains massive unmet clinical 
need in developing, emerging and developed 
countries. there is, for example, a pressing need 
for effective vaccines against HIV⁄aIds, malaria 
and tuberculosis. we have nothing to prevent the 
inexorable decline in neurological function in people 
with neurodegenerative disorders such as alzheimer’s 
disease, Parkinson’s disease or Huntington’s disease. 
and, when effective vaccines and treatments have 
been developed, they are too often unavailable to 
those in the poorer parts of the world. during most 
of the second half of the 20th century, research-
based pharmaceutical companies were, for practical 
purposes, the sole source of new medicines. they 
discovered, developed and delivered products – 
often with considerable ingenuity – for healthcare 
systems that were able to afford the costs required 
to maintain the industry’s infrastructure.
People in poorer countries, unable to meet these 
costs – as well as lacking an appropriate healthcare 
infrastructure – only rarely benefited. the prospect 
for satisfying unmet medical need has, in some 
senses, never been brighter. advances in molecular 
techniques offer the promise of identifying drug-
sensitive targets that might attenuate or cure many 
miserable and life threatening conditions. the massive 
chemical libraries available to most pharmaceutical 
companies, coupled with high throughput screening 
and combinatorial chemistry, offer unimaginable 
rewards for us all. In addition, the emergence of an 
array of biotechnological techniques offers unique 
approaches to the development of innovative 
medicines.
Yet, despite the promise from the science, the 
outlook is not favourable. despite record investment 
in biomedical research by the public sector and not-
for-profit organizations, as well as by pharmaceutical 
and biopharmaceutical companies, the number of 
new active molecules registered by drug regulatory 
authorities has fallen dramatically. the costs of 
bringing a new product to the market are increasing 
at a rate of 10% per annum, due in part to the 
failures of products during development, but also 
to the extended requirements for evidence-based 
documentation from regulatory authorities (e.g. in 
elderly patients). added to this, many of the largest 
pharmaceutical companies face large reductions in 
turnover as their ‘blockbusters’ come off patent. 
there have also been spectacular withdrawals 
of some marketed medicines because of safety 
concerns. as a consequence, drug regulatory 
authorities have become increasingly risk averse and 
place ever greater demands on manufacturers to 
demonstrate the safety of their products before and 
after marketing. while this may have some benefits 
for drug safety, these measures are likely to increase 
the cost of medicines unless they are implemented 
with considerable care. moreover, healthcare systems 
across the world are struggling to meet the apparently 
high prices that pharmaceutical companies seek to 
charge for new products that do reach the market. 
those responsible for meeting the health needs of the 
populations they seek to serve are under increasing 
pressure to provide affordable care. the increasing 
numbers of elderly and very elderly people (many 
the global medicine scene: 
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with long-term chronic diseases requiring multiple 
drug therapy), the greater availability of effective 
screening measures (especially in the elderly), and 
the growing expectations of the public, all mean that 
resources are constrained. one of the reasons for the 
rapid emergence of Hta facilities, across europe and 
north america, is because of the necessity to look 
ever more closely at the clinical efficacy and cost-
effectiveness of therapeutic strategies.
I tHe FUtUre ProsPects
despite this gloomy outlook, a number of initiatives 
suggest that remedial action is being taken: 
 
1.  drug regulatory authorities themselves recognise 
the need for change if people are to have access 
to innovative medicines. Both the Food and drug 
administration in the United states (19) and the 
european medicines agency (ema) in the eU 
(20) have published plans for expediting the 
regulatory process of innovative medicines that 
are appropriately safe and effective.
2.  the process of drug discovery, confined for 
most of the 20th century to the laboratories of 
research-based pharmaceutical companies, has 
become much more pluralistic. In particular, 
academic scientists working in universities have 
become ‘drug hunters’ and some have been 
spectacularly successful. whereas 25 years ago, 
major pharmaceutical companies were unwilling 
to even contemplate developing products 
that had not been discovered in their own 
laboratories, they are now prepared to do so with 
enthusiasm. Indeed, companies are pursuing truly 
collaborative projects with academic scientists to 
the extent that they are allowing access to their 
chemical libraries.
3.  an increasing number of not-for-profit 
organizations such as the Bill and melinda gates 
Foundation (in seattle) and the Hereditary disease 
Foundation (in new York) are supporting drug 
discovery and development in co-operation with 
both academia and pharmaceutical companies.
4.  some major pharmaceutical and biopharmaceu-
tical companies are increasingly recognising that 
their traditional models of discovery, development 
and pricing no longer meet the needs of patients, 
healthcare systems or their shareholders (21). 
changes include moving away from seeking 
‘blockbusters’; expanding sales to include the 
emerging markets in asia; and discussing, with 
healthcare systems themselves, what future 
products would bring most value for money. 
I conclUsIons
these changes in the global medicines scene require 
the contributions of appropriately trained clinical 
pharmacologists if innovative new medicines are to 
reach those in need:
1.  clinical pharmacologists should be better 
equipped to undertake ‘translational’ research, 
especially the design and execution of Phase 1 
studies.
2.  too few contemporary clinical pharmacologists 
are actively engaged in the design and conduct 
of clinical trials. the founding fathers of the 
discipline (such as lou lasagna (13)) made crucial 
contributions to health care by undertaking clinical 
trials – often in relatively small patient populations 
– that characterised a compound’s properties 
(especially dose–response relationships).
3.  with a few notable exceptions, the discipline of 
Hta has emerged in the absence of contributions 
from clinical pharmacology. this needs to change 
if Hta is to meet its full potential.
4.  clinical pharmacologists could do so much more 
to meet the health needs of those peoples who 
have in the past been marginalised. they include 
children, the elderly, those with rare diseases and 
those with conditions that are endemic in the 
poorest parts of the world.
I IntrodUctIon
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the ways in which clinical pharmacological services 
could be integrated in healthcare systems were first 
outlined in 1970 in a wHo technical report referred 
to earlier (1).
the quality and outcome of drug therapy in patient 
care can be greatly improved by using cost-effective 
and evidence-based treatment with drugs adapted 
to the needs of patient populations and individual 
patients. advances in drug development provide 
patients with new drugs, novel drug combinations, 
expensive biological drugs and targeted drug therapy 
adapted to the molecular characteristics of the disease 
(22,23,24). Increasingly cost-effective generic 
drugs are available and should be used as first-
hand therapies to balance the economic pressures 
on all healthcare systems today (25). the rate of 
implementation of this strategy varies widely across 
health care systems (25). easy access to evidence-
based drug information will assist physicians and 
healthcare staff in monitoring the effectiveness and 
safety of drug therapy and optimal allocation of limited 
resources (26,27).this is a priority since patients and 
patient organizations are eager to explore what 
new therapies can offer in terms of health benefits 
compared to existing treatments, but new drugs 
and drug combinations may not be affordable for all 
patients and healthcare institutions. It needs also to 
be considered that newly registered drugs are rarely 
innovative (24,27). as a result, great emphasis must 
be placed on the overall cost-effectiveness and safety 
of new drug therapies from a societal perspective in 
order to guide drug selection and reimbursement 
decisions (22,28). the use and value of new drug 
therapies have to be monitored within the healthcare 
institutions as part of a systematic introduction and 
follow-up of new therapies by involving drug experts 
across medical specialties and systematic use of 
clinical outcome data (24,28). such a procedure will 
diminish the gap between documented efficacy in 
controlled clinical trials and observed effectiveness 
in clinical care (24,28). clinical pharmacology with 
its emphasis on critical drug evaluation, scientific 
methodology, drug development and involvement 
in the work of drug and therapeutics committees 
is strategically positioned to bridge the knowledge 
gap between stakeholders including patients, 
clinicians, pharmacists, administrators, politicians 
and pharmaceutical companies within and outside 
healthcare institutions (26,27).
the quality of drug therapy can be improved in all 
healthcare settings irrespective of the resources of the 
country or of individual health care facilities. Patients 
can be provided with effective and safe therapy if well-
documented drugs are prescribed, and the drugs are 
used according to medical, social, environmental and 
financial circumstances. the gap between knowledge 
about drugs and their use in clinical practice needs 
to be reduced in order to promote the principles 
governing the rational Use of medicines (rUm). 
these principles have to be communicated, learnt and 
practiced by students, doctors, healthcare staff and 
patients in their daily clinical practice (24,27,29,30). 
an optimal strategy for eliminating the knowledge–
practice gap in drug therapy is to apply a multifaceted 
approach including practice-governed quality 
assurance programmes combined with interactive 
continuous medical education and prompt electronic 
access to evidence-based guidelines (24,27,31). 
the principles of rUm have to be integrated with 
healthcare planning and with resource allocation 
given the scarcity of resources that healthcare 
institutions are facing. clinical pharmacologists with 
their focus on drug evaluation and on the principles 
of rUm are needed in patient care (22,27,28,29). 
they should train healthcare staff in the principles of 
drug evaluation and promote the use of guidelines 
and drug recommendations based on scientific 
evidence. at the level of individual hospitals and 
the clinical 
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healthcare institutions, limited resources cannot be 
used effectively and safely without a local knowledge 
and the practice of the principles of critical drug 
evaluation among clinicians and pharmacists (26,27). 
decisions on drug use and reimbursement for 
specific indications can rationally be adapted to local 
circumstances in health care facilities by involving key 
medical opinion leaders at a local level supported by 
clinical pharmacologists and pharmacists trained in 
critical drug evaluation (27,29,30,31). In doing so, 
unbiased decisions free from improper influence by 
special interest groups is particularly important in 
view of the relentless increase in the promotion and 
cost of new drugs (27).
I  keY clInIcal PHarmacologY 
serVIces In PatIent care 
the form these services take may vary from country 
to country and facility to facility depending on the 
professional and financial resources available. the 
key bodies providing overall coordination and control 
of these services are the drug and therapeutics 
committee (dtc) and clinical Pharmacology 
departments at hospitals or in primary care. 
therefore, all health care facilities should have a well-
developed dtc with clear instructions, resources and 
a comprehensive approach (27,32).
(a) Critical evaluation of new and old therapies 
is fundamental for patient care. It should be a core 
activity in clinical consultations, in the provision of 
drug information, in services to dtcs, in consultations 
with clinical colleagues ⁄clinics, in drug selection and 
in the design of clinical trials. critical drug evaluation 
is the cornerstone for rUm and is important in rich as 
well as in resource-poor settings. the role of critical 
drug evaluation is particularly important when new 
and expensive drug therapies and drug combinations 
are introduced (see also chapter 12). 
critical drug evaluation assists the practicing physician 
in rating the strength of documentation about 
efficacy, safety and cost-effectiveness for a specific 
drug therapy as compared with alternative therapies. 
the method of critical drug evaluation requires 
medical, clinical pharmacological and scientific skills 
(13, 26, 27). applying critical evaluation methods 
in local health care settings is complementary to 
evaluations by drug registration bodies. key elements 
of critical drug evaluation include assessment of the 
quality and completeness of a clinical drug study. 
By using a rating scale (0, 1, 2) this methodology 
can assist healthcare staff to assess the value of a 
specific drug therapy in clinical practice (33). In 
short, an evaluation of a clinical drug study should 
preferably include rating of the following aspects: 
- aims of the trial
- relevance of the trial for health care
-  the quality and precision of criteria for diagnosis 
and selection of patients 
- the type of controls used in the study
- the quality of the design of the study
- adequacy of randomisation to treatment 
- the quality of pharmacokinetics data
- drug-drug interactions problems if any
- how adequately drug effects were recorded
-  how well adverse effects were monitored and 
evaluated
- the quality of statistical planning and analysis
-  the precision of conclusions of study results and 
shortcomings
 
By applying this procedure it is feasible to rate  the quality 
of a drug study with a maximum of 24 points that will 
help to guide the clinician about the strength of a specific 
clinical drug study and drug therapy. It will be possible to 
choose between suggested drug therapies by comparing 
outcomes of ratings of several clinical drug studies. 
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(b) Drug and Therapeutics Committees (DTC)
all institutions, no matter what size, should have 
some appropriate version of a dtc. It should 
preferably recruit both hospital based specialists and 
primary care physicians in order to provide the same 
type of recommendations irrespective of the level 
of healthcare (26,27). the membership will vary 
depending on local circumstances and resources 
but may include physician clinical pharmacologists, 
relevant medical staff, clinical and other pharmacists 
and other staff as appropriate. where available, 
physician clinical pharmacologists provide a 
leadership role bridging medical, pharmacy and other 
staff (26,27). dtcs should issue recommendations 
for drug use within the facility based on scientific 
evidence and medical needs at the local level. this 
will usually take the form of a local formulary or 
”Wise List” with the wHo essential drug concept 
being a useful model (27,34).
(c) Drug utilisation studies and pharma-
coepidemilogical services are closely linked to 
the work of dtcs and to quality assurance of drug 
therapy in clinics and in hospitals (30, 35). Ideally, 
a multi-professional approach is preferred involving 
experts in clinical specialties, pharmacoepidemiol-
ogy, pharmacoeconomics and clinical pharmacology. 
these services are important for a systematic intro-
duction and monitoring of new drug therapies in the 
facility and can then be linked to forecasting future 
drug use in healthcare organisations. knowledge 
about the use of drugs is a prerequisite for follow-
up studies of the adherence of prescribers to drug 
recommendations and of the effectiveness of drug 
information and educational activities (27,30,35).
(d) Drug information services are primarily 
targeted to guide clinicians in evaluating and solving 
drug problems in patients. the services provided 
are usually both descriptive and problem oriented. 
the latter, addressing problems at a patient level 
are appropriately provided by physician clinical 
pharmacologists or clinical pharmacists depending on 
the availability of staff at the particular facility. drug 
information services build on systematic literature 
searches in databases and reference books combined 
with an evaluation of the literature on patient-related 
diagnostic problems. this service should assist dtcs 
in literature searches as the foundation of evidence-
based drug recommendations. a drug information 
service is also helpful for provision of unbiased 
drug information in academic drug detailing, which 
is well documented to improve adherence to drug 
recommendations and guidelines and should be part 
of the activities of the dtcs (36).
(e) Services in pharmacovigilance may 
include the responsibility to be a coordinating 
centre for reports of adverse drug reactions (adrs) 
from clinicians and other prescribers at a regional or 
national level (37). adr reports should be evaluated 
systematically and the conclusions fed back to the 
reporting clinicians and the dtc. regional clinical 
pharmacology centres for pharmacovigilance have 
been successfully implemented in countries such as 
France and sweden (37). Pharmacovigilance should 
be given priority in resource poor settings when 
implementing population based therapies to control 
major infectious diseases such as HIV/aIds, malaria 
and tuberculosis (38). 
(f) Continuing medical education. the focus 
should be on major pharmacotherapeutic areas, on 
the principles of rUm and on new drug therapies 
and drug combinations. Interactive models for 
learning such as integration of e-learning tools in 
academic drug detailing and open access internet 
should be considered and will help to improve the 
quality of knowledge in drug therapy in remote 
healthcare institutions in resource poor countries. 
continuing medical education should preferably be 
interactive as this will foster the best involvement of 
clinical colleagues.
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(g) Therapeutic drug monitoring (TDM) and 
pharmacogenetic services ideally involve the 
participation of a division or department of clinical 
Pharmacology. tdm services should always involve 
clinical interpretation of the data taking diagnosis, 
drug-drug interactions, kidney function and 
pharmacogenetics into consideration. an important 
service, particularly for elderly patients, is to ensure 
that drug dosages are adapted to the reduction 
in kidney function that occurs with age (see also 
chapter 8). an example of successful translation of 
the scientific development of pharmacogenetics into 
the clinic is the abacavir hypersensitivity syndrome 
which now can be prevented (39). moreover, 
the discipline of personalised medicine is rapidly 
growing, particularly in the field of cancer.
(h) Measurement of drug concentrations 
for the diagnosis and prevention of drug 
abuse and other toxicological services. In 
many hospital settings, clinical pharmacologists are 
involved in toxicological services such as diagnosis 
and treatment of drug intoxication. although the 
availability of causal treatment with antidotes is 
limited, a correct diagnosis of the drug involved 
through drug analysis is important for follow-up and 
future prevention. a new function in some countries 
is to participate in the prevention of the abuse of 
doping agents such as anabolic steroids among 
athletes and in society at large (40).
(i) Direct Patient Services. clinical 
pharmacologists provide care for patients in a 
variety of ways. In some countries, physician clinical 
pharmacologists take responsibility for the direct 
care of patients with particular clinical problems 
(e.g. intensive care), in patients with particular organ 
diseases such as hypertension or areas such as 
paediatrics and geriatrics. In some countries, clinical 
pharmacologists are mainly used for their skills in 
the evaluation of clinical drug problems such as 
therapeutic polypharmacy. clinical pharmacologists 
can assist in the development, implementation and 
evaluation of efficacy and safety of combination 
therapies in the treatment of major infectious diseases 
such as HIV⁄aIds, tuberculosis and malaria. In both 
rich and poor countries, drug abuse problems cause 
considerable harm (41). Preventive programs as well 
patient care require access to clinical pharmacological 
expertise supported by adequate drug analytical 
resources.
(j) Electronic Pharmacological (e-Pharmaco-
logical) Services. evidence-based databases for 
rational drug prescribing are now available through 
websites in many countries (42,43). they can be 
integrated into electronic medical journals and 
linked to lists of prescribed drugs. e-pharmacological 
services include tools, knowledge databases on 
drug recommendations, drug–drug interactions, 
drugs to be used in pregnant or lactating women, 
adrs and tools for the solution of drug related 
problems. e-pharmacological services provide 
a link between published evidence and clinical 
practice. these services are predicted to become of 
particular importance with the accelerating spread 
of mobile phones and internet access in lesser 
developed countries and will, in the future, require 
extension to the public and to patients (24). this 
multidisciplinary field will be of great importance 
in resource poor settings where the clinical 
pharmacological community with a natural global 
professional network can help to provide electronic 
drug information from different countries. the 
contents of e-pharmacological services are heavily 
dependent on expertise in critical drug evaluation. 
drug therapy in Paediatric Patients
clinical Pharmacology in Health care, teaching  and research 17
the well-known paediatric therapeutic disasters of 
the late 1950s (eg sulfisoxazole, chloramphenicol) 
revealed the need and gave the impetus for the 
development of paediatric clinical pharmacology. 
despite the fact that training of paediatric 
clinical pharmacologists has been going on for 
decades, training capacity remains very small. 
consequently the number of trained paediatric 
clinical pharmacologists in the world is relatively 
small, with the majority of countries having only a 
handful if any (44). In this context, paediatric clinical 
pharmacologists are physicians with training in both 
paediatrics and clinical pharmacology. However, 
over the past two decades, professionals outside the 
discipline of medicine but who possess specialised 
expertise that is germane to the field of paediatric 
clinical pharmacology have entered the discipline 
and participate in a variety of settings (eg academic, 
regulatory, clinical and industrial).
the need for more and better development, scientific 
study, regulatory assessment and appropriate use 
of paediatric medicines is recognised in the Us, 
eU, and wHo paediatric medicines initiatives. 
Implementation of all the paediatric studies 
mandated by these initiatives requires well trained 
investigators and other experts (eg research 
trained nurses, pharmacists, laboratory scientists) 
which in many countries do not exist in numbers 
sufficient to embrace the demands associated with 
paediatric drug development. accordingly, building 
enhanced capacity and strength in paediatric clinical 
pharmacology across the world is essential to ensure 
the success of these initiatives.
 
I  deFInItIon oF PaedIatrIc 
clInIcal PHarmacologY
Paediatric clinical pharmacology is a scientific 
discipline that involves all aspects of the relationship 
between drugs and humans during growth, 
development and maturation. Its breadth includes 
the continuum between discovery, development, 
regulation and utilisation of medicines (as regards 
compounds and formulations) intended to benefit 
the paediatric population. as well, paediatric clinical 
pharmacology is concerned with the response to 
and the adverse effects of medicines, their use 
and misuse, and the economics of drug therapy. 
as the great majority of scientific research and 
drug development is for many reasons first done in 
adults, paediatric clinical pharmacology adds the 
translational element of adapting scientific methods 
and translating scientific information from adults to 
paediatric patients (45).
By virtue of the comprehensive scope of paediatric 
clinical pharmacology, it involves numerous 
professional groups whose training and skills 
are relevant to one or more of the scientific and/
or clinical facets of the discipline of paediatric 
clinical pharmacology (eg physicians, biomedical 
scientists, and non-physician health care providers 
such as nurses and pharmacists). Paediatric clinical 
pharmacology is therefore a scientifically driven field 
of endeavour that depends on a variety of skilled 
professionals with a training or special interest in 
appropriate aspects of paediatric drug therapy.
 
I  scoPe oF PractIce In PaedIatrIc 
clInIcal PHarmacologY
Practice environments for paediatric clinical 
pharmacology are diverse and can include patient 
care, research, teaching, drug development and drug 
regulation. Paediatric clinical pharmacologists may 
participate directly in the care of paediatric patients 
as either primary care givers or consultants, or may 
work in scientific and/or administrative capacities to 
improve the quality of medicines use irrespective of 
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the health care setting or the wealth of the country. at 
the country level, paediatric clinical pharmacologists 
can provide valuable service in the development 
of national medicines Policies that consider the 
special issues of the paediatric population. these 
issues include the rational Use of medicines (rUm) 
in paediatric drug therapy and measures to protect 
the basic human rights of paediatric patients who 
participate in medicines research. their involvement 
often extends to the regulatory assessment of 
paediatric medicines, the development of national 
treatment guidelines, proposing inclusion of 
paediatric medicines in reimbursement lists, and 
monitoring of the performance of medicines in 
different clinical settings after regulatory approval 
(eg through the application of pharmacoepidemiology, 
pharmacovigilance and pharmacoeconomic  principles) 
to assess impacts on health outcomes.
It should also be recognised that, globally, more than 
a third of the population in developing countries, 
and almost half in the least developed countries are 
in the paediatric age range (less than 18 yrs). close 
to 9 million children die every year before their 5th 
birthday from diseases that are usually amenable 
to treatment. In the area of priority diseases like 
HIV/aIds, malaria and tuberculosis, children lag 
far behind adults in their access to appropriate 
medicines, especially where the large part of 
the burden of disease is borne by the paediatric 
population (eg malaria). recognising that children 
represent the hope of 100% of the world for its 
future, it is essential that their special needs with 
respect to the development and implementation of 
safe and effective drug treatment be fully embraced. 
to this end, the enhanced availability of the expertise 
and services that can be provided by paediatric 
clinical pharmacologists represents a critical need on 
a global level.
I  traInIng In PaedIatrIc clInIcal 
PHarmacologY
Paediatric clinical pharmacology is a sub-discipline 
of clinical pharmacology and paediatrics. It is a 
recognised paediatric medical sub-specialty in at 
least the Uk (46) and australia. Individuals in other 
professional groups can also receive training and 
certification in specific areas related to paediatric 
drug therapy through their professional associations. 
Finally, it must be emphasised that training in 
paediatric clinical pharmacology must extend beyond 
the development of specialist paediatric clinical 
pharmacologists. It is vital that educational curricula 
for all health care professionals involved in the 
treatment of infants and children contain appropriate 
components of the principles of paediatric clinical 
pharmacology. similar educational components 
should also be included in undergraduate medical 
programs and in paediatric medical and surgical 
sub-specialty postgraduate training programs. 
the continued development of programs and 
practitioners of paediatric clinical pharmacology is 
essential for these broad educational goals to be 
accomplished throughout the world.
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the most rapidly expanding age group world-wide 
is those 80 years and older (47). multiple concurrent 
illnesses that may benefit from drug treatment 
are the rule, not the exception, in this group. the 
likelihood of adverse drug reactions increases 
markedly as the number of concurrently administered 
drugs rises. this combined with the age-related 
decline in physiological functions (decreased cardiac 
reserve, impaired baroreflex function, decreased 
immunological response, decreased renal function) 
that in younger patients may reduce the severity of 
an adverse drug reaction, make the older patient 
particularly at risk for polypharmacy related adverse 
drug reactions (48). However the benefits for the 
treatment of hypertension, coronary artery disease, 
congestive heart failure, diabetes, arthritis, and other 
chronic illnesses associated with advancing age are 
well established. clinical pharmacologists who focus 
their research, teaching and clinical service toward 
older individuals have the opportunity to improve 
rUm for this increasingly important segment of the 
world’s population.
during the past 30 years, clinical pharmacologists 
have conducted the research that has defined 
the pharmacokinetics of aging (49). this work, 
particularly in the area of drugs (or their metabolites) 
that undergo renal clearance, has contributed 
importantly to patient safety and well being. For 
many drugs it is essential to assess renal function 
in order to choose the appropriate dosage. looking 
to the future, the research opportunities to define 
drug pharmacodynamics and altered drug harm/
benefit relationships in older patients are abundant. 
similarly, teaching rUm for older patients and 
placing this into a geriatric medicine perspective is 
an important role for the clinical pharmacologist. 
the number of physicians trained as geriatric clinical 
pharmacologists is inadequate to meet either the 
research or educational needs, and attracting 
physicians and training them to do geriatric clinical 
pharmacology is a continuing challenge.
clinical pharmacology has an important role to foster 
the linkage of the principles of geriatric medicine and 
disease-based therapeutics. In geriatric medicine, 
advances in understanding the interplay of multiple 
concurrent illnesses and how these may result in a 
common path to patient disability and death have 
allowed definition of the frailty syndrome (50). In 
addition, the concept of competing morbidity such 
that in the older patient successful treatment of 
one illness may result not in restoration of health, 
but in the more obvious clinical presentation of 
another concurrent illness, has advanced clinical 
decision making and end of life care. the clinical 
pharmacologist has an important role in teaching 
about the changing balance of harm and benefit 
for specific drug therapy intervention in the context 
of the individual older patient and their specific 
concurrent illnesses. the research opportunities in 
this area for the clinical pharmacologist are both 
challenging and exciting. research efforts by clinical 
pharmacologists that have been translated into 
improved clinical practice for older patients include 
the development of expert opinion developed lists 
of drugs to use such as the “wise list” (27) and the 
Beers criteria (51). In addition, based on extensive 
drug usage data, clinical pharmacologists in europe 
have developed “Unwise lists” of drugs that are 
best avoided in older patients. geriatric clinical 
pharmacologists also develop research tools such as 
the “drug Burden Index” (52) that link anticholinergic 
and sedative drug exposure to important clinical 
functional outcomes in older patients.
disease-based therapy focuses on the development 
and implementation of treatment guidelines to 
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optimise treatment for a specific illness. clinical 
pharmacologists and geriatric medicine specialists 
have pointed out that implementation of treatment 
guidelines for each of the diseases of an older patient 
leads to extreme polypharmacy when multiple 
diseases are present. often concurrent implemen-
tation of multiple therapy guidelines result in 
conflicts, contradictions, and the simultaneous use of 
drugs that are known to have harmful pharmacokinetic 
and/or pharmacodynamic interactions (53,54).the 
geriatric clinical pharmacologist brings the appropriate 
training and knowledge base to either resolve these 
therapeutic dilemmas, or to conduct the research 
needed to achieve optimal patient care.
the multidisciplinary health care team is championed 
by geriatric medicine as the optimal means of providing 
care for the complex older patient with multiple 
concurrent illnesses. the clinical pharmacologist has 
a key role on this team, working closely with the primary 
geriatric medicine clinician, the clinical pharmacist, and 
other members of the team to individualise and modify 
complex drug therapy regimens as the clinical status 
of the older patient evolves over time.
as the population ages in developing countries, the 
role of the clinical pharmacologist assumes even greater 
importance.  therapeutic decision-making for older 
patients with multiple illnesses that may benefit from 
drug therapy must be considered in the context of 
limited resources and the desire to provide effective and 
cost-effective treatment.  Here too there are excellent 
opportunities for the clinical pharmacologist to team 
up with specialists in geriatrics and other health care 
team members to provide the best pharmacological 
care to the largest number of older patients.
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I  IncreasIng demands on 
PrescrIBers oF drUgs
For most physicians, drug therapy is the main tool at 
their disposal to influence the health of their patients. 
new graduates are typically expected to start 
prescribing drugs regularly as soon as they begin 
their first medical post. the prescribing demands 
placed on this group in healthcare systems have 
progressively increased because of many important 
trends:
•  the number of drugs available continues to rise so 
that physicians often have to prescribe drugs with 
which they are less familiar.
•  Patients are taking more drugs, increasing the 
complexity of their treatment regimen and the 
potential for drug interactions.
•  medication errors and adrs, many of which are 
avoidable, constitute a major challenge to public 
health.
•  Patients who receive drugs are older and sicker, and 
more vulnerable to adverse events.
•  Patient throughput is increasing (matched by a 
similar increase in prescribing episodes) imposing 
higher workloads on individual prescribers.
•  the expansion of evidence-based medicine and 
Hta has enabled the beneficial and harmful effects 
of drugs to be quantified more accurately, and this 
knowledge has expanded the number of clinical 
guidelines that define norms of acceptable drug 
use.
•  Patients increasingly expect their physicians to 
provide information about the drugs they are being 
given to inform their own choices about treatment.
•  Poor access to trained medical staff in developing 
and emerging countries.
•  Increasing problems with poor quality drugs and 
combination therapies for chronic diseases such 
as HIV ⁄aIds and tuberculosis in developing and 
emerging countries, in particular in africa.
•  there are more sources of opinion and 
‘disinformation’ available to patients and 
prescribers, largely as a result of increasing access 
to the internet.
•  the marketing activities of pharmaceutical 
companies remain a potential threat to cost-effective 
prescribing decisions and are complicated by direct-
to-consumer advertising in some countries.
Prescribing drugs is a skilled task that always carries a 
risk of significant harms as well as benefits. although 
newly qualified physicians are usually protected 
from the requirement to undertake high-risk practical 
procedures, they are often expected to prescribe 
powerful drugs from their first day of clinical work. 
Indeed, these inexperienced doctors typically write 
most hospital prescriptions in many healthcare 
systems. It is clear that all medical graduates should 
have a firm grounding in the principles of practical 
prescribing, as underpinned by the science of clinical 
pharmacology, at the point of graduation, as the basis 
for rational prescribing.
the primary determinant of the effectiveness of 
a prescriber in most areas of practice will be the 
education and ability of a prescriber to respond 
to changes in pharmacotherapy. the increasing 
support of other healthcare professionals, such 
as pharmacists, and the availability of prescribing 
support systems and electronic prescribing will help 
the prescribers in their task but they are no substitute 
for education and training.
several studies have shown that lack of training 
and familiarity with drugs among prescribers is an 
important factor in serious medication incidents 
(6,55). new graduates rate prescribing as the most 
challenging aspect of their profession and the one 
for which they are least well prepared. Importantly, 
educational interventions such as the ‘wHo guide 
to good Prescribing’ have been shown to improve 
prescribing performance.
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I  UndergradUate edUcatIon 
a key aim of undergraduate medical education 
should be to provide the learning opportunities 
that will enable all students to acquire the requisite 
knowledge, skills and attitudes, and also to put 
in place appropriate assessments to ensure that 
these outcomes have been achieved. as the rate of 
drug development increased in the 1960s, clinical 
Pharmacology and  therapeutics (cPt) emerged as 
a new teaching discipline and many medical schools 
incorporated it into their curricula as a distinct 
course. most medical schools provide some teaching 
in both basic and clinical pharmacology, the former 
during the early years and the latter during the 
later clinical years of the medical curriculum. when 
students start clinical training, they have usually 
passed examinations in basic pharmacology and are 
expected to understand the principles of drug action 
(56-59).
the core content of a curriculum in cPt can 
be conveniently divided into knowledge and 
understanding, skills and attitudes with emphasis 
on critical drug evaluation (see addendum I). most 
of these outcomes are generic requirements for the 
safe and effective use of drugs in all areas of clinical 
practice. these core cPt learning objectives can be 
linked to a number of specific drugs and therapeutic 
problems which might be used to provide relevant 
clinical examples of the principles of cPt in practice. 
teaching about specific drugs is organised in different 
ways in different countries.
one model is to focus teaching on a selected 
list of the most commonly prescribed 50–100 
drugs that will be influenced by the pattern of 
disease in the country concerned. these should be 
selected in such a way that their pharmacological 
properties reflect the important pharmacodynamic 
and pharmacokinetic principles on which rational 
drug use should be based. the list could be close 
to a national drug list (2), a regional list for ‘wise 
drug Prescription’ (27) or the wHo essential drug 
list (34) but will normally contain far fewer drugs 
than such lists. an extensive list of drugs should 
be avoided as the professional prescription of 
drugs will be practiced several years later when the 
prescribers have chosen their specialty. specific lists 
of drugs that should be familiar to the prescribers 
will then differ between, for example general 
practitioners, internists, psychiatrists and oncologists. 
Postgraduate and continuing education in clinical 
pharmacology rather than undergraduate education 
will thus determine the drugs that are commonly 
prescribed. However, an understanding of the basic 
principles of cPt should allow physicians to take a 
logical approach to learning about any of the drugs 
they will encounter during their practice.
the principal recommendations for the delivery of 
cPt in the undergraduate medical curriculum are 
summarised below:
•  cPt and prescribing (or equivalent) should be 
identified as an important component of the 
curriculum, visible to students in all years, either 
as an identified course itself or a theme that 
integrates with other modules.
•  core learning objectives in cPt should be clearly 
identified including knowledge and understanding 
about drugs, skills related to the prescribing of 
drugs and attitudes towards pharmacotherapy.
•  the factual burden posed by the large number 
of drugs should be eased by prioritising learning 
around a core list of commonly used drugs (a 
‘student formulary’), similar to the process used 
by the wHo in developing their ‘essential drugs’ 
policy.
•  there should be an identifiable and robust 
assessment that indicates whether the main 
learning objectives have been met. this might form 
part of an integrated assessment but it should not 
be possible to compensate for a poor performance 
in this area by a good performance in other items.
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I  stUdent FormUlarY
medical students are often overwhelmed by the 
large number of drugs that they encounter during 
their training. this can be demoralising and lead 
to a lack of clarity and objectivity in learning. as 
suggested above, a potential solution is to develop 
a list of core drugs that could be considered as the 
‘student formulary’ that helps to prioritise study and 
provide learning objectives that are realistic and 
attainable. this has already been done in a number 
of medical schools in europe, the Us, and elsewhere. 
the list should contain 50–100 drugs that are 
commonly prescribed and used to treat common 
diseases. For each drug or group of drugs, students 
might be expected to have an understanding of the 
mechanism of action, recognise the appropriate 
indication and contra-indication, know about 
potential interactions and adverse effects, know how 
to monitor effects and be able to explain the salient 
features of all the above to the patient. the students 
should also learn about the principles for stopping 
irrational drug therapy. the list of core drugs can be 
organised by organ system and set alongside the 
common therapeutic situations in which they are 
used. this arrangement emphasises the suitability 
of a problem-based approach to develop learning 
about cPt and the ease with which cPt can be 
integrated within a system-based curriculum.
I  delIVerIng tHe core cPt 
cUrrIcUlUm 
Variability in the structure of medical courses will 
require local solutions for delivery of the cPt 
curriculum. where there are traditional arrangements, 
there may be a preclinical phase containing scientific 
disciplines that include pharmacology and later 
courses in ‘cPt’ or ‘pharmacotherapy’ and this model 
is straightforward. delivery is more challenging 
when the traditional barriers have been removed 
in the production of a truly integrated curriculum, 
often with an emphasis on problem-based learning. 
In these circumstances, cPt learning objectives 
must compete simultaneously with many others, 
usually dispersed across many different modules 
and through several years of the course. this poses 
practical difficulties for cPt teachers coordinating 
learning opportunities across many modules over 
which they have limited influence. nevertheless, 
the importance of cPt should be emphasised in 
all clinical modules in which there are continuous 
opportunities to observe and appraise critically the 
patient drug charts, see the beneficial and harmful 
effects of drugs and practice relevant skills (e.g. 
prescribing, dose calculations, drug preparation 
and administration, and searching for good quality 
information to inform prescribing decisions).
I  cPt leadersHIP
a key factor in the successful implementation of the 
cPt core curriculum, particularly in an integrated 
course, will be strong and enthusiastic leadership. 
all medical schools should be able to identify an 
individual who will oversee delivery and ensure 
that the generic principles of safe and effective use 
of drugs are highlighted throughout the course. 
this role should ideally be undertaken by a senior 
individual with a background and training in cPt, 
helped by colleagues in the discipline some of 
whom may be trainees in cPt. In medical schools 
without cPt departments, other specialists with an 
enthusiasm for ensuring that principles of cPt are 
prominent throughout the curriculum should be 
identified.
the coordination of cPt learning opportunities can 
be devolved to many teachers across the course, 
often within organ-based specialties. they too 
should be encouraged to emphasise these principles 
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and remind students about the effects of drugs 
beyond individual organ systems. simply providing 
a link between drugs and clinical conditions is 
insufficient to develop an appreciation of the complex 
considerations that surround the decision to initiate 
a prescription.
all schools should ensure that, in each case, 
students are helped to tackle the practical issues of 
weighing the harms and benefits of drug therapy, 
prescribing the drug and monitoring the impact 
of therapy. clinical pharmacists who are usually 
available in greater numbers than physician clinical 
pharmacologists also have an important role to play 
in reinforcing learning during clinical attachments, 
working with other pharmacotherapeutic experts.
I  learnIng stYles 
the successful delivery of the core curriculum may 
involve a variety of learning styles (e.g. lectures, 
problem-based tutorials) depending on local 
preference but the content should increasingly be 
based around inquisitive rather than passive learning. 
there should be an appropriate balance of teaching 
in large groups and small groups, practical classes 
and opportunities for self-directed learning. the core 
curriculum in cPt is well suited to take advantage 
of the increasingly popular style of problem-based 
learning.
most prescribing episodes are a direct attempt to 
solve a clinical problem and require the appropriate 
knowledge, skills and attitudes outlined in 
addendum I. several schools have developed a 
series of ‘therapeutic case discussions’ that offer 
students a case vignette and pose direct problems 
relating to prescribing and therapeutics. these can be 
undertaken in live time, even within relatively large 
groups, or researched and discussed at intervals 
over several weeks. other approaches to cPt 
involve writing case reports containing discussion 
about therapeutic aspects (e.g. portfolio cases), 
discussing prescribing decisions with patients as 
part of communication skills, critiquing clinical trials 
involving drugs, appraising claims for new drugs and 
searching for information about drugs.
I  e-learnIng 
many cPt departments have now embraced web-
based approaches as an opportunity to deliver 
learning opportunities and self-assessment in 
cPt. certainly, it is important that students should 
be exposed to and trained in the principles of 
electronic retrieval of reliable drug information. 
computer-assisted learning packages are 
constantly accessible. as the change from paper 
to electronic prescribing spreads worldwide, aided 
by advances in virtual reality environments, this 
approach will be able to provide increasingly 
realistic simulation of real-world therapeutics (60). 
an e-learning approach is foreseen to be of high 
relevance in resource-poor countries with chronic 
lack of educated staff. Innovative teachers should be 
able to use the academic high-speed networks for 
provision of distance learning, interactive teacher–
student contact. this may also be applicable in many 
developing countries.
I  assessment
assessment drives learning and is critical in 
emphasising the importance of cPt in the course 
and ensuring that graduates are fit to practice. 
all medical schools should have validated and 
reliable schemes of assessment in place to ensure 
that students demonstrate that they have achieved 
the curricular outcomes. It is important too that 
assessments should not simply be knowledge-
based but test the acquisition of practical skills 
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(e.g. writing a prescription, offering information 
to a patient about a drug and spotting potentially 
dangerous prescriptions). the objective structured 
clinical examination (osce) is an ideal format for 
this kind of assessment. relatively few schools now 
have a traditional cPt examination as changes to the 
curriculum bring the assessments of diverse learning 
objectives together in integrated examinations. 
where this is the case, there should be a clear, 
identifiable and robust component devoted to 
the knowledge and skills that support rational 
prescribing. Furthermore, whether assessment 
is integrated or part of a collection of discipline-
based assessments, it is normally not appropriate 
for students to be able to compensate for a poor 
performance in prescribing or therapeutics with good 
performances in other assessments. students should 
also be provided with formative assessments and the 
chance for self assessment at regular intervals during 
the medical course.
I  QUalItY assUrance 
all schools should have some form of external 
quality assurance to ensure that the cPt learning 
opportunities and assessments they provide are fit 
for purpose, i.e. deliver graduates with sufficient 
knowledge and skills. such reviews might examine 
whether the goals outlined earlier in this section have 
been met. the appointment of external examiners 
with cPt expertise might also help to ensure that 
appropriate standards are met.
I  PostgradUate edUcatIon 
education in cPt and prescribing should be a 
continuing process in postgraduate medicine, not 
only because of the constant emergence of new 
medicines but also rapid changes in the knowledge 
base of those that are already established in clinical 
practice (see addendum II).
the previous section outlines the importance 
of developing a firm platform on which to 
build postgraduate training. there should be 
a progression from undergraduate training for 
broad-based, supervised prescribing through to 
progressively specialised and less supervised work 
during subsequent years. curricula for specialist 
training and related assessments will be critical in 
promoting the importance of cPt principles and 
knowledge. In the case of specialists in primary 
care or hospital-based disciplines, arrangements for 
continuing medical education (cme) (often known 
as continuing Professional development) will be 
important in updating knowledge and skills and 
fostering reflective practice. the emergence of new 
prescribing groups (e.g. pharmacists, nurses) in 
some countries offers a further opportunity for cPt 
education to be used to enhance health care.
there are several important challenges for 
postgraduate cPt education. Perhaps the greatest 
is to find the necessary time in already busy clinical 
schedules. However, this problem is being increasingly 
circumvented by the development of more flexible 
web-based learning solutions and recognition within 
the relicensing⁄revalidation process that all doctors 
require protected time for cme. another important 
challenge is to provide good quality non-promotional 
education. recent years have seen pharmaceutical 
companies play a well-resourced highly influential 
role in the delivery of unbiased postgraduate 
education. clinical pharmacologists should embrace 
the opportunity to contribute to the planning of non-
promotional educational events.
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I  IntrodUctIon 
In the first wHo report on clinical pharmacology in 
1970 (1), the section on research emphasised the 
need for studies that explored the mechanisms of 
action of drugs and identified their pharmacokinetics 
in humans. Improvement of the early studies of 
new drugs in humans and conventional therapeutic 
trials were also prioritised. research in clinical 
pharmacology has now taken new paths and this 
satisfies many principles of translational medicine 
defined as taking scientific data on drugs into rational 
patient care.
However, we should be aware that not all research into 
drugs falls within the remit of translational medicine. 
the endeavour of a pharmacologist working in a 
clinical environment is to develop methods and 
strategies that improve the quality of drug use in 
individual patients and patient populations. research 
in drug evaluation, drug utilization, pharmacovigilance 
and pharmacoepidemiology – areas that were only 
superficially mentioned in the 1970 document are 
now the priority. all these research areas have great 
potential for supporting healthcare personnel in their 
rUm. rational use of medicines implies that drugs 
should be chosen according to efficacy, adrs and 
cost as potentially equally important parameters. 
research in clinical pharmacology therefore also 
includes studies that elicit new data about drugs 
in use, such as new indications and treatment of 
neglected patient populations (children, elderly - see 
chapter 7 and 8). It also includes research into adrs, 
pharmacogenetics and drug interactions. research in 
clinical pharmacology is usually interdisciplinary and 
hence often carried out in collaboration with other 
professionals: pharmacists, drug analytical chemists, 
molecular biologists, statisticians, computer 
specialists as well as clinical researchers from other 
medical specialties.
I  PHarmacokInetIc, 
PHarmacodYnamIc and 
PHarmacogenetIc stUdIes In 
HUman VolUnteers
this research should lead to a fundamental 
understanding of the mechanisms involved in the 
actions of the drugs on the organism or the actions of 
the organism on the drugs. the research is particularly 
focused on intra- and interindividual differences in 
pharmacokinetics and pharmacodynamics, an area in 
which clinical pharmacologists have made important 
contributions in the past. the mechanisms in such 
variability usually involve inherited individualities in 
the genes encoding drug targets, drug transporters 
and drug metabolising enzymes. the perspective of 
the research should not only be in understanding 
the molecular mechanisms but also in designing 
genotyping or phenotyping tests, which may be 
applied to forecast drug response and to differentiate 
between genetic and non-genetic modifiers of the 
outcome of drug treatment . In vivo research is often 
combined with experimental studies in vitro and in 
silico. the research aims to identify the routes of 
metabolism and excretion of drugs.
there are two separate approaches in pharmacoki-
netic research, one based on several drug 
measurements over a fixed time schedule in a 
few subjects and the other being based on sparse 
measurements in each subject of a large population of 
individuals (population pharmacokinetics). such data 
may help to identify subpopulations with impaired 
or enhanced elimination capacity. the population 
approach can also be applied to pharmacokinetic–
pharmacodynamic evaluation. 
10research domains of clinical Pharmacology
Clinical Pharmacology in Health Care, Teaching  and Research28
I  clInIcal drUg eValUatIon and 
clInIcal trIal PHases I–III
Important research areas are to improve the 
methods used to evaluate drugs in humans. the first 
examination of the effects of a new drug in humans 
(Phase I) is done with great care and in great detail, 
few subjects being tested. these Phase I studies are 
often done by clinical pharmacologists working in 
industry or in specialised clinical trial units. when 
the time comes to examine the effect of the drug 
in patients with the disease to be treated (e.g. 
hypertension), again small numbers of patients will 
be studied in detail (Phase II studies). the training 
that clinical pharmacologists undergo gives them the 
skills to do such studies.
the randomised controlled trial (rct) or its extension 
to meta-analysis or systematic reviews of several 
rcts is considered to be the gold standard for 
documenting the efficacy of drugs. the rct has 
advantages but also disadvantages and other 
methods for the evaluation of clinical interventions 
are needed (61). clinical pharmacologists have 
been the pioneers in introducing the rct and in 
particular in introducing the placebo as control. 
the rct is now mastered by clinical intervention 
researchers in practically all medical specialties 
and is no longer solely the province of clinical 
pharmacologists. the rct is a method with which 
all clinical pharmacologists should be familiar as it 
still forms the basis of most drug evaluations. one 
area in which clinical pharmacologists could make a 
difference is the detection of relatively frequent adrs 
that are predictable and understandable on the basis 
of the mode of action of the drug. another area is the 
evaluation of biomarkers as measures of drug action 
in clinical trials. In the case of new drugs, the studies 
described above are part of the Phase I clinical trials.
I  tHeraPeUtIc drUg monItorIng 
(see also cHaPter 6)
therapeutic drug monitoring (tdm) is a scientific 
medical technology where clinical pharmacology 
has made major contributions. the measurement 
of drug concentrations in blood or plasma will often 
help to achieve better understanding of the nature 
of individual drug exposure, how this relates to 
expected exposure values at the given dose, and 
recommended target ranges in plasma at which there 
is an optimal therapeutic effect or an increased risk of 
adrs. therefore, the clinical use of tdm is obvious 
for drugs that have a narrow therapeutic window and 
for which individual exposure is difficult to predict 
from the particular dose used owing to extensive 
interindividual differences in pharmacokinetics. It 
may provide direct guidance for individual dose 
adjustments in cases of adrs or therapeutic failure. 
tdm is based on the assumption that the plasma 
concentration of the drug reflects the concentration 
at the drug target, although this may not always 
be the case, for instance with some central nervous 
system (cns)-active drugs or anti-infective agents 
used to treat localised tissue infections. 
tdm research into clinical routine samples has been 
important for a safer use of specific drugs in subgroups 
of patients at risk: the elderly, children and patients 
with renal or hepatic failure. tdm research has also 
helped to detect and manage drug–drug interactions 
and to understand the clinical impact of genetic 
polymorphisms in drug elimination pathways.
the mapping of the human genome and the 
revolutionary developments in biotechnology and 
human molecular medicine have been of fundamental 
importance in this regard. research at the beginning 
of the 21st century mainly aims at understanding the 
role of genetic variation in the capacity or function of 
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drug metabolising enzymes, drug transporters and 
receptors and their relationship to the clinical effects 
of drug treatment. many tdm laboratories now 
offer genotyping services, in addition to tdm, and 
medical input is crucial for an individualised, clinical 
interpretation. 
clinical pharmacologists need to understand the 
principles of the laboratory methods that are used, 
although they may not necessarily be able to 
perform them. In experimental studies on tdm or 
pharmacogenetics, the main responsibility of the 
clinical pharmacologist is to formulate a clinically 
relevant problem, design the study that will help 
to bring further understanding to this problem, be 
medically responsible for the study volunteers and 
translate the results into clinical practice.
I  PHarmacoVIgIlance 
when a new drug enters the market, it has been 
tested in only 3–5000 patients. there ought to be 
solid documentation that its actions are superior 
to placebo or comparable to or even better than 
the existing treatment. Its most common harmful 
effects should be known, in particular those that 
are predictable from their basic pharmacological 
properties or readily explained in the context thereof. 
However, at marketing, serious or even lethal but 
very rare adrs that cannot be explained by the basic 
pharmacology of the drug and that occur in, say, 1 
out of 10,000 patients or even less commonly, may 
not have occurred or been recognised. spontaneous 
adr reporting is carried out in order to detect 
unknown potential drug toxicity. the method 
consists of collecting individual case reports of clinical 
suspicions of adrs. data mining in adr research is 
the search for structures and patterns in large adr 
databases, manual inspection no longer being 
possible. data mining involves the development, 
testing and implementation of computer methods, 
routine algorithms and tools for finding such 
associations and patterns of associations between 
drug intake and adverse events.
I  drUg UtIlIsatIon stUdIes
clinical pharmacologists play a key role in drug 
utilisation research, which can be defined as an 
eclectic collection of descriptive and analytical 
methods and theories for the quantification, 
understanding and evaluation of the processes 
of prescribing, dispensing and consumption of 
medicines. the subject is also concerned with the 
testing of interventions to enhance the quality 
of these processes. It is common to quantify drug 
utilisation by defined daily doses, which by definition 
is the typical maintenance dose of the drug in an 
adult for its main indication.
I  PHarmacoePIdemIologY 
sometimes an rct is either unethical (e.g. in 
detecting harmful effects on the foetus) or impossible 
because hypothesis testing or signal generation 
will require very large numbers of patients. clinical 
pharmacologists have been pioneers in establishing 
pharmacoepidemiology, which may be defined as 
the science of studying the utilisation and actions of 
drugs in large populations. Pharmacoepidemiology 
uses methods from both clinical pharmacology and 
epidemiology. the purpose of the research may be to 
detect a signal, to estimate the risk of an adr or to 
test a hypothesis. the results of the research can be 
used to give advice to healthcare organisations and 
individual patients or to formulate a policy regarding 
the optimal use of the drug.
cohort studies are carried out by registering a drug 
effect (cure, death, adr) in a sample of patients 
treated with a particular drug. a sample of patients 
not treated with the drug is used as a control group. 
random allocation and blinding are not applied 
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and that presents problems with confounding and 
bias but methods have been developed to at least 
partly overcome this. In case-control studies, drug 
use in patients with a symptom suspected of being 
an adr is compared with drug use in a sample of 
patients without the symptom. thus, the odds ratio 
for developing an adr can be calculated. linkage 
studies are carried out by linking data from individual 
level prescription databases to health outcome 
databases. Pharmacoepidemiology is an important 
new development in clinical pharmacology. For 
the sake of the continued development of the 
scientific discipline, it is important that part of 
pharmacoepidemiology be anchored in clinical 
pharmacology.
I  PHarmacoeconomIcs 
Pharmacoeconomics is the scientific discipline that 
evaluates the clinical, economic and human aspects of 
pharmaceutical products, services and programmes 
as well as other healthcare interventions. the 
aim is to provide healthcare decision-makers, 
providers and patients with valuable information for 
optimal outcomes and the allocation of healthcare 
resources. Pharmacoeconomics incorporates health 
economics, clinical evaluations, risk analysis, 
technology assessment and health-related quality 
of life, epidemiology, decision sciences and health 
services research in the examination of drugs. 
clinical pharmacologists are important in the field 
of pharmacoeconomics as they are best placed to 
formulate research questions of medical importance 
and to translate the research findings into effective 
treatment with sensible outcome measures for 
the average patient. the main role of a clinical 
pharmacologist in this discipline is to assess the 
quality and suitability of clinical trials data for 
inclusion in the overall analysis, in order to determine 
whether a new drug has any clinical advantage over 
the existing treatments. It is necessary to arrive at 
an objective quantitative evaluation of ‘benefit’ or 
‘effectiveness’ to put into cost-effectiveness models 
that health economists have developed. the clinical 
pharmacologist is uniquely able to do this evaluation 
which may end up not conforming to the appraisal 
or claim submitted by manufacturers.
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I  BackgroUnd
the growing importance of biopharmaceuticals, is one 
area in which the remit of the clinical pharmacologist 
has expanded very significantly since the original 
wHo document appeared in 1970. In the last three 
decades, drugs produced or extracted from biological 
sources (e.g. recombinant products, monoclonal 
antibodies and recombinant vaccines) such as insulin, 
somatotropin, interferon, granulocyte-stimulating 
factor, erythropoiesis-stimulating factors like epoetin 
and tumour necrosis factor – alpha (tnF-alpha) and 
inhibitors like infliximab have been developed and 
approved for therapeutic use. Biopharmaceuticals 
are a rapidly growing segment of newly developed 
drugs, with sales amounting to about $40 billion in 
2006 in the United states (62) . today, 20–30% of 
drugs are produced by biotechnological methods. 
the patent on human insulin was filed in the early 
1980s and expired in 2002. other patents have also 
ended or are about to expire. currently, about 400 
biopharmaceuticals are under clinical development 
about half of which are used in treating cancers. 
as many of them are expensive, it is important that 
generic products can be provided to make cost-
effective treatment accessible to all those who need 
them. 
In contrast to classical drugs, which are typically 
manufactured by chemical synthesis, biologics 
(or biopharmaceuticals) are manufactured in a 
living system such as a micro-organism or plant 
or animal cells. owing to their production process 
and mechanism of action, biologics have a different 
pattern of potential adverse effects compared with 
chemically synthesised drugs, and these adverse 
effects deserve special attention (63).
most biologics are very large, complex molecules 
or mixtures of molecules. the production is usually 
based on recombinant dna technologies and the 
process is often commercial-in-confidence (62). 
changes to the production process such as cell lines 
used, vectors, culture media and conditions can lead 
to the formation of protein isoforms, alteration of 
glycosylation patterns and/or changes in the tertiary 
protein structure. therefore, unlike classical drugs, 
a medicine produced by such a process in order to 
mimic an already licensed biologic (the reference 
drug) is a product that is similar to but not the same 
as the innovator drug. therefore, such a product 
is not called ‘generic’ but ‘biosimilar’ or ‘follow-on 
biologic’.
Because of the complex science involved, the ema 
recognised that the usual approach to generic 
medicines is scientifically not appropriate for these 
products. clinical pharmacologists working in this 
field posess or need to acquire knowledge and skills 
in molecular and cell biology rather different from 
those needed previously.
I  BIosImIlars – ProBlems In 
eValUatIon
as biosimilars are different from existing biologics 
in terms of their raw materials and manufacturing 
processes, biosimilars have the potential to cause, 
for example, immunogenicity problems that were 
not detected in clinical trials and did not occur with 
the original manufacturer’s product. therefore, ema 
has stipulated that a regulatory framework should 
be established to minimise the risk to patients by 
requiring extensive testing before approval in order 
to ensure that biosimilars are safe and effective. 
moreover, biosimilars have to undergo post-
marketing monitoring like that required for new 
biologics. accordingly, ema has taken a case-by-
case approach to similar biological products, typically 
requiring new clinical trials. the Fda is given some 
flexibility in deciding how much data and testing are 
enough to establish the key standards of safety and 
efficacy – similarity and interchangeability - for follow-
on biologics (64). In particular, the manufacturer of a 
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biosimilar has to provide a detailed pharmaceutical 
dossier, including data on the manufacturing process, 
manufacturing facilities, implementation of non-
clinical bioassays, toxicity studies, local tolerability 
studies, and Phase I to Phase IV studies compared 
with the reference product. thus, for biosimilars of 
epoetin, ema stipulated two double-blind studies 
in a parallel group design to investigate the efficacy 
of the new erythropoiesis-stimulating agent in 
patients with anaemia following renal damage. 
generally, it is permitted to extrapolate results on 
efficacy in a specific therapeutic area to others, e.g. 
from renal anaemia to the symptomatic treatment of 
chemotherapy-associated anaemia. However, this 
may vary between agencies and from time to time. 
as mentioned above, immunogenicity is a major 
problem of biologics. as they are proteins, an 
immune response such as the formation of 
antibodies is more likely than in conventional 
pharmaceutical products. thus, in patients treated 
with epoetin alpha, an isolated erythroblastopenia 
(pure red cell aplasia) has occurred as a consequence 
of the generation of neutralizing antibodies against 
erythropoietin (65). In general, the immunogenic 
potential of biopharmaceuticals depends on the 
production process, and also on the mode of 
application, dosage, duration of treatment and 
specific characteristics of the individual patient. 
therefore, careful pharmacovigilance is needed, as 
immunological reactions may be without clinical 
consequences, or may sometimes lead to a loss of 
efficacy, without causing severe adverse reactions. 
according to ema guidelines, at least 300 patients 
must be observed over at least 12 months in order 
to assess possible immunogenicity and the profile 
of adverse events of a biosimilar compared with the 
reference substance (66).
as the safety data from pre-authorization studies 
are never sufficient to get a complete profile of 
the immunogenic potential of a biosimilar, post-
authorization safety studies and the preparation of 
risk management plans are obligatory for biosimilars.
to illustrate the differences of approval for biosimilars 
of epoetin, abseamed (medice, Iserlohn, germany) 
and Binocrit (sandoz, kundl, austria) were approved 
in europe except for subcutaneous injection in 
patients with chronic renal failure, as data on 
immunogenicity were considered to be insufficient 
for this indication. this exception does not exist for 
the biosimilar epoetin alfa Hexal (Hexal, Holzkirchen, 
germany).
I  conclUsIons
the extensive requirements of regulatory 
authorities concerning preclinical and clinical 
studies of biosimilars impose substantially higher 
developmental costs than those for usual generic 
drugs. It is therefore expected that biosimilars may 
save only 15–20% of costs compared with the 
biopharmaceutical original (67).
In summary, the assessment of the harm benefit 
ratio of biologics and biosimilars is a challenge for 
physicians, manufacturers and regulatory authorities 
and requires translational efforts to consider the 
needs of drug innovation on the one hand and patient 
safety on the other hand (68). It requires the expertise 
of molecular biologists, immunologists and clinical 
pharmacologists in order to take advantage of these 
challenging new medications. the opportunities for 
clinical pharmacologists in this field are considerable 
provided the necessary training in molecular and cell 
biology is taken on board in addition to the standard 
training that clinical pharmacologists undergo. 
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I  oVerVIew and tHe IndUstrY 
enVIronment 
Pharmaceutical companies have until recently driven 
the discovery, development and marketing of new 
and established drugs. they include a range of 
organisations varying from ‘big pharma’ global 
companies such as Pfizer and glaxosmithkline, 
to smaller, usually disease-focused, specialised 
companies, large (e.g. genentech) and small 
biotechnology companies, and companies focused 
on generic, over-the-counter (otc) or complementary 
medicines. the clinical pharmacologist has a 
broad perspective of all aspects of drug discovery 
and use, and all of the ‘sub-specialities’ of 
clinical pharmacology from pharmacokinetics ⁄ 
pharmacodynamics to pharmacoepidemiology, 
pharmacovigilance (benefit ⁄ harm management) and 
pharmacoeconomics are critical. more importantly, 
the clinical pharmacologist can integrate knowledge 
of the drug target, disease pathophysiology, context 
and management and preclinical and clinical data to 
guide drug development in an ethical, informed and 
efficient manner.
globally, pharmaceutical companies operate in a 
complex environment where evolving economic, 
regulatory, social and political influences constantly 
force change. Investment in r&d increases rapidly, 
but is not matched by the rate of emergence of new 
products onto the market. the high expectations 
of innovation models that involve combinatorial 
chemistry, high-throughput screening, rational 
drug design, pharmacogenomics, bioinformatics 
and disease and pathway modelling have not been 
met despite the high level of investment. the risks 
in a business model that concentrates on a few 
‘blockbuster’ drugs are also apparent as patents 
expire or are challenged vigorously by generic 
companies, and new drug pipelines to replace them 
are meagre. there have also been highly visible 
failures of potential blockbusters at a late stage in 
development and a number of high-profile safety-
related post-marketing drug withdrawals that have 
resulted in an increased regulatory focus on risk 
management during the drug development process. 
at another level, consumers, health insurers and 
governments are increasingly focusing on paying for 
health outcomes rather than drugs, and sales and 
marketing approaches used in the industry are being 
questioned with a resulting reduction in trust. what 
changes are being driven by these factors?
at the discovery level, there is recognition that 
diseases are complex and that a focus on single 
targets may not be the optimal approach, resulting 
in a move back to disease models rather than 
target-based r&d. the separate silos of discovery, 
preclinical development and clinical development are 
increasingly integrated vertically into development 
teams that include functions from early discovery 
through to pharmacoeconomics and marketing. 
companies are emphasising translational research 
to facilitate the efficient transition from in vitro and 
preclinical animal research to human applications, 
and medicines are developed for more tightly 
targeted patient groups who are identified as likely to 
respond using biomarkers and ⁄ or pharmacogenomic 
approaches, thus improving the cost-effectiveness of 
the treatment (so-called ‘personalised medicine’). 
companies increasingly market medicines coupled 
with related services and diagnostics to identify 
responsive patients, and there is recognition of 
developing markets and neglected diseases as targets 
for drug development and marketing. the focus 
of payers on cost-effectiveness drives companies 
towards development of medicines that produce real 
health benefits, and the biotechnology paradigm 
replaces the chemical, with biologicals providing 
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high benefits coupled with high value and cost. 
‘Big Pharma’ is accessing biotechnology medicines 
through in-house r&d, licensing, sponsored r&d, 
partnerships and the acquisition of small, vigorous, 
fast moving and innovative biotechnology companies 
that have often been started by academics.
despite the problems facing the industry, the 
demand, and therefore the market, for medicines 
is likely to rise during the second decade of the 
21st century owing to ageing populations and the 
emergence and growth of new markets particularly in 
developing countries. companies are consolidating 
through mergers and acquisitions and this trend is 
set to continue. Paradoxically, they may become less 
homogeneous, with niche market, biotechnology 
and generics companies all emerging as significant 
players.
I  roles For clInIcal 
PHarmacologIsts In IndUstrY
clinical pharmacologists can work in a wide range 
of roles across companies, but will need to develop 
skills and expertise beyond those normally associated 
wit the discipline in the academic or hospital setting. 
the types of roles available, and the knowledge, 
skills and attitudes required are discussed below.
Traditional roles: the clinical pharmacologist in 
industry customarily has been involved at the early 
stages of clinical drug development – planning, 
design, conduct, analysis, interpretation and 
reporting of Phase I and Phase II studies in humans. 
these activities include:
•  First in human trials, involving the first exploration in 
humans of dose, tolerability and pharmacokinetic 
and (where appropriate) pharmacodynamic 
parameters. the clinical pharmacologist works 
with preclinical, translational medicine ⁄ biomarker, 
drug metabolism⁄Pk, and toxicology partners 
to synthesise all the available data, to plan the 
optimal Phase I strategy for clinical development, 
and eventual filing for marketing approval.
•  Phase II proof of concept clinical trials to establish 
efficacy in a restricted patient population
•  Follow-up on Pk⁄Pd studies exploring issues such 
as drug interactions, effects of disease states, 
bioavailability and ⁄ or bioequivalence of dosage 
forms used during early and late development, 
and special patient groups such as the elderly or 
children.
Specialised roles: clinical pharmacologists have 
diverse areas of special interest within the discipline, 
and many of these roles and skills are needed by the 
pharmaceutical industry (69-71). given their broad 
training and background, clinical pharmacologists 
are well placed to integrate their special area of 
interest across functional and therapeutic area 
groups. some examples are:
• Preclinical development
• Pharmacogenetics
• Pharmacoepidemiology
• Pharmacovigilance (benefit ⁄ harm management)
• Pharmacoeconomics
•  late clinical development – Phase III confirmatory 
trials.
Other activities: clinical pharmacologists in 
industry contribute to greater or lesser extents in a 
range of other activities which may include: 
•  regulatory – preparation of submissions, 
interactions with regulatory authorities and 
regulatory strategy planning.
•  outsourcing – managing cro and academic 
contracts.
Clinical Pharmacology in Health Care, Teaching  and Research 35
•  advisory – arranging and managing scientific 
and clinical advisory boards, interactions with key 
scientific and clinical advisers to ensure appropriate 
product development.
•  Intellectual property management – assisting 
with the preparation of patents, liaising with 
patent lawyers and responding to queries from 
patent offices around the world; involvement in IP 
protection strategies including decisions to patent, 
retain as in-house know-how or put in the public 
domain; scientific and clinical advice for patent 
defence.
•  due diligence activities – involvement in scientific 
and clinical analysis of data and the scientific, 
clinical and market potential of products or 
companies.
•  management and financial activities – human 
and physical resources – planning most efficient 
development paths – quicker development gives 
higher net present value.
Roles in small pharmaceutical or bio-
technology companies:
the clinical pharmacologist is needed in this setting 
to fulfil a much broader role, being involved in 
overall discovery, development and marketing. the 
company will often function in a specific therapeutic 
area with a small number of products in development 
and ⁄ or on the market. the role will usually involve 
a broader strategic planning, management and 
financial focus. clinical pharmacologists are needed 
to contribute to many aspects of the overall business, 
including raising funding on the financial markets, 
development strategies in relation to funds available, 
and making decisions about developing to market 
stage, or licensing or sale of the product at an earlier 
development stage.
Industry roles and needs. Pharmaceutical 
companies usually have distinct scientific and 
management career streams. clinical pharmacologists 
will normally start in the scientific stream, but are well 
placed because of their broad background to contribute 
in both areas. clinical pharmacologists are needed 
in roles including managing a project or product 
development team, leading a therapeutic area such 
as cns or cardiovascular system (cVs), or leading a 
functional area such as clinical pharmacology, benefit 
⁄ harm management or pharmaco epidemiology. the 
broad perspective of clinical pharmacologists is ideal 
for higher management roles with involvement in 
the company’s overall discovery, development and 
marketing strategies.
Knowledge, skills and attitudes. the clinical 
pharmacologist in industry normally has basic training 
as a physician with specialist training in clinical 
pharmacology. companies provide training in-house, 
or externally, for necessary industry-specific skills such 
as project management, but much is gained through 
hands-on experience. the areas involved may include:
• Intellectual property and knowledge management.
• strategic planning and project management.
•  regulatory requirements – international, regional 
and country-specific.
•  regulatory compliance – gxPs, electronic and hard 
record data and information management.
•  leadership and decision-making in complex 
organizations and cross-functional teams.
•  core business skills – including the structure of the 
industry, a broad understanding of the business 
issues and models in the industry, the differences 
between industry sectors, and how product value 
is created and measured.
•  ethical and societal perspectives and broad industry 
issues – attitudes and ethical practices in a company or 
industry sector, medical versus marketing department 
perspectives, values and activities.
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the goal of drug development is to convert 
intellectual and scientific creativity into medicines 
that are valuable in terms of both benefits to patients 
and a sustainable business model for the company. 
the clinical pharmacologist has the background 
to influence industry practices along appropriate 
ethical, societal and medical lines, even though this 
may be difficult in the context of a large, financially 
driven organisation. 
clinical Pharmacology in Health care, teaching  and research 37
the clinical pharmacologist is an individual who has 
had systematic training in the evaluation of drug 
therapy and drug products. this makes the specialty 
suitable and valuable in a number of government-
based public activities that relate, for example, to 
drug approval, post-marketing surveillance, drug 
therapy selection, reimbursement decisions and 
ethical review of research projects. governments 
should be involved in the ethical, scientific and 
developmental aspects of medicines. activities in 
all these three dimensions are complementary and 
underpin the most important role of any government: 
to protect its citizens through support and promotion 
of public health.
governments and their respective institutions have to 
take all necessary measures to make sure that clinical 
research involving its citizens is not doing them harm 
or ignoring their basic human rights. this challenging 
task involves making sure that the research to decide 
which medicines (or other healthcare interventions) 
are authorised for use in human beings provides 
enough grounds to ensure safety. It also involves the 
task of assessing whether planned clinical research 
follows scientific principles that can justify both the 
harms and the expected benefits from this research. 
this forms the ethical dimension of the role of 
governments.
I  HIstorY
Following the two world wars, several initiatives 
were taken around human rights and these were 
embodied in the world medical association’s 
declaration of Helsinki in1964. In particular, the 
council for International organizations of medical 
sciences (cIoms) was founded under the auspices of 
wHo and the United nations educational, scientific 
and cultural organization (Unesco) in 1949. In the 
late 1970s, cIoms set out, in cooperation with wHo, 
to prepare guidelines ‘to indicate how the ethical 
principles that should guide the conduct of biomedical 
research involving human subjects, as set forth in the 
declaration of Helsinki, could be effectively applied, 
particularly in developing countries, given their 
socioeconomic circumstances, laws and regulations, 
and executive and administrative arrangements. 
the most important of the publications of cIoms 
is its International ethical guidelines for Biomedical 
research Involving Human subjects, first published 
in 1993. the updated version was published in 
2002 (72) and is designed to be of use, particularly 
to resource-poor countries, in defining the ethics of 
biomedical research, applying ethical standards in 
local circumstances, and establishing or redefining 
adequate mechanisms for the ethical review of 
research involving human subjects. although 
mainly targeting ethics committees sponsors and 
investigators, the cIoms guidelines, to which several 
clinical pharmacologists have contributed, have 
influenced the thinking of governments concerning 
clinical research, especially in resource-poor settings.
another important facet of research in human subjects 
is good clinical practice (gcP) which is a ‘standard 
for the design, conduct, performance, monitoring, 
auditing, recording, analysis and reporting of clinical 
trials. gcP provides assurance that the data and 
reported results are credible and accurate, and that 
rights, integrity and confidentiality of trial subjects 
are protected’. many gcP guidelines are based on, 
or refer to, the declaration of Helsinki, including 
wHo gcP guidelines published in 1995 (73) and 
the International conference of Harmonization (IcH) 
gcP (e6) from 1996 (74).
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I  etHIcs commIttees and 
regUlatorY BodIes
a fundamental requirement for the application of 
ethical considerations is submission of a research 
proposal to independent evaluation by an ethics 
review committee. nowadays, many governments 
define procedural aspects of the work of ethics 
committees in detail. For example, the european 
commission has laid down strict timelines for 
processing research applications which affect the 
work of ethics committees in all european Union 
member states. clinical pharmacologists are 
particularly valuable as members of ethics review 
committees because of their knowledge of medicines-
related clinical research. In addition, governments 
have to ensure that only effective, safe, good quality 
medicines are used to treat their citizens. nowadays, 
all medicines are subject to marketing authorization 
approval before they are prescribed. the approvals 
are based on assessment of the quality, safety and 
efficacy of the products. the safety monitoring 
of medicines during their whole life cycle (from 
marketing authorisation to potential withdrawal 
from the market) is also a task for governments. 
Usually, these and other medicines-related 
regulatory functions are carried out by specialised 
governmental agencies – national medicines 
regulatory authorities (nmra) such as the Us Food 
and drug administration (Us Fda) and in europe, 
the ema. In a broad sense, the role of the nmra 
is to cover multiple dimensions and is derived from 
their mission. wHo Policy Perspective on medicines 
no. 7 ‘effective medicines regulation: ensuring 
safety, efficacy and Quality’ (75) states the following: 
“a clear mission statement, which includes the 
national regulatory authority goals, is necessary to 
guide its work. goals usually include the protection 
and promotion of public health by ensuring the 
safety, efficacy and quality of medicines, and their 
appropriate use; and ensuring the appropriateness 
of medicines information provided to the public and 
health professionals.”
the ema which coordinates the work of the various 
national experts in europe and has very far reaching 
responsibilities, has a broader mission statement 
(76):
 ‘‘ to foster scientific excellence in the evaluation and 
supervision of medicines, for the benefit of public 
and animal health” by  
•  developing efficient and transparent procedures to 
allow rapid access by users to safe and effective 
innovative medicines and to generic and non-
prescription medicines through a single european 
marketing authorization;
•  controlling the safety of medicines for humans and 
animals, in particular through a pharmacovigilance 
network and the establishment of safe limits for 
residues in food-producing animals;
•  facilitating innovation and stimulating research, 
hence contributing to the competitiveness of eU-
based pharmaceutical industry; and
•  mobilising and coordinating scientific resources 
throughout the eU to provide high-quality 
evaluation of medicinal products, to advise on 
research and development programmes, to 
perform inspections for ensuring fundamental 
gxP (gxP means ‘good clinical practice’ (gcP), 
‘good manufacturing practice’ (gmP) and ‘good 
laboratory practice’ (glP) collectively) provisions 
are consistently achieved, and to provide useful 
and clear information to users and healthcare 
professionals’’.
these are two examples of mission statements. 
the one from ema addresses the three aspects 
described above, namely ethical, scientific and 
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developmental concerns. It is very important that 
regulators involved in the evaluation of safety and 
efficacy of medicines have the best possible scientific 
education and background. they should also be able 
to make a critical scientific evaluation of the clinical 
data and to understand what, at the time of the 
assessment, is known and what remains unknown 
about each drug under review. some nmra also 
have units focusing on clinical pharmacology. For 
example, the U.s. Fda has in its centre for drug 
evaluation and research (cder), the office of clinical 
Pharmacology. nowadays, safety surveillance and 
pharmacovigilance are also the responsibility of the 
regulators.
 
I  clInIcal PHarmacologIsts  
In goVernment
In most countries, governments, directly or through 
their specialised agencies, are also involved in 
taking decisions about the selection of medicines for 
public procurement, developing national treatment 
guidelines and proposing inclusion of medicines 
in reimbursement lists. this work may also involve 
composing and updating national essential 
medicines lists as promoted by the wHo. clinical 
pharmacologists are usually closely involved at the 
government level in developing and delivering a 
national medicines Policy. It is important that such 
individuals work in an environment that has political 
support but also where there is a good prospect of 
continuity of support when governments change.
the monitoring of the performance of drugs in 
real life after regulatory approval, including cost-
effectiveness assessment in the wider context of 
Health technology assessment (Hta) needs highly 
qualified specialists. However, all these activities 
are linked to promotion of the rational use of 
medicines, sometimes also called ‘quality use’ (77). 
an example of governmental institutions involved 
in such activities is the national Institute for Health 
and clinical excellence in the United kingdom. the 
activities of such bodies should be based on the best 
possible scientific methods and knowledge and are 
part of the scientific dimension of the government’s 
obligation to its citizens. clinical pharmacologists 
have proved themselves to be well prepared to 
meet the challenges of the complex assessment of 
medicines.
working at the government level, clinical 
pharmacologists are well trained to work in the area 
of Hta. many of the assessments are very much 
in the field of new drug assessments, especially 
the new molecular biology drugs, as well as in the 
administration of drugs by new technologies. recent 
history gives evidence that not all the research 
necessary for developing and promoting public 
health by medicines is possible using only private 
sector initiatives and funding. thus, governments 
may also be involved in delivering financial support 
for clinical research involving medicines. clinical 
pharmacologists are well positioned to make 
judgements about the scientific value of proposals 
for government funding of research projects. an 
important emerging issue is electronic patient health 
records which have been implemented or are on 
their way in many countries.
although these may be perceived as mostly 
administrative tools, they include a huge scientific 
potential for monitoring the safety and quality 
of drug therapy. there is already evidence that 
electronic health records can offer greatly added 
value for research in pharmacovigilance (78). clinical 
pharmacologists should be actively involved in 
designing and using electronic patient health records 
because of the enormous potential for future clinical 
research including monitoring of rational drug use 
and safety.
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I FUtUre cHallenges 
a government’s efforts to create a research-friendly 
environment in its country should be composed 
of functional legal and other systems which will 
make government offices well informed about the 
necessary scientific background, and thus help their 
effective functioning.
owing to the relative lack of new therapies 
and pressure from patient groups and industry, 
governments have been pushed into granting ‘early 
market approvals’ under certain pre-conditions. 
However, effective methods for pharmacovigilance 
and safety studies in the context of early market 
access need to be created and tested and clinical 
pharmacologists have an important role to play 
(79,80). clinical pharmacologists also contribute to 
the topic of pharmacoepidemiology. this discipline 
is being increasingly used and sometimes is the 
only available approach to assess the benefits and 
harms of long-term pharmacotherapy. similarly, 
pharmacoeconomics attempts to give a financial cost 
and value to everyday drug use which may become 
the basis for rational reimbursement systems.
In order to implement these various dimensions, 
governments have to create laws and regulations, 
the necessary infrastructure in terms of governmental 
institutions and necessary resource allocations to 
support the infrastructure. one of the key resources 
is properly trained specialists, capable of taking 
decisions based on the best possible scientific 
methods and evidence. all these dimensions are 
inter-related and interdependent. good ethics 
cannot do without good science; good science can 
be ethical, whereas bad science can never be.
I conclUsIons
the clinical pharmacologist is a specialist who, 
working at government level, serves the public 
interest by helping to ensure that only safe and 
effective medicines are authorised for use, as well as 
facilitating cost-effective prescribing and improving 
the rUm. the training of clinical pharmacologists 
is ideal for these purposes and can be tailored to 
meet the needs of various government services in 
order to ensure that the best scientific knowledge is 
used to make decisions in public health. In particular 
the governments of emerging economies and 
developing countries will benefit from the applied 
expertise of clinical pharmacologists. However, few 
have given the necessary priority to the development 
of the discipline of clinical pharmacology, and many 
have difficulty in creating positions that compete for 
funds with disciplines that may be seen to be more 
‘mainstream’.
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 “traditional medicine” is a comprehensive term used 
to refer to various forms of indigenous medicine - 
including traditional chinese herbal medicine, african 
traditional medicine, ayurvedic and Unani medicine, 
homeopathy, naturopathy and other administered 
treatments derived from natural sources (81). It also 
covers manipulative physical treatments which are 
not considered here.
clinical pharmacology arose in the universities of the 
western world where modern prescription and over-
the-counter medicines were the sole entities studied 
and where the expectation was that trained clinical 
pharmacologists would teach, investigate, and have 
clinical expertise in, the use of such medicines. most 
clinical pharmacologists in practice today will have 
had little or no exposure to traditional medicines 
unless they have sought it out for themselves.
In the 40 years since wHo published its first 
technical report on clinical Pharmacology (1), the 
use of traditional (‘complementary’, ‘alternative’) 
medicines has grown rapidly in developed countries 
many of which have now created national regulatory 
bodies to set standards for their quality and safety.
although access to conventional medicines in 
developing countries has improved, it is still 
estimated that a third of the world’s population, 
which is almost exclusively in developing countries, 
has inadequate access to “essential medicines”. 
therefore, in the developing countries the majority 
of the population still relies on traditional medicines 
and its practitioners.
However, the involvement of clinical pharmacologists 
in traditional medicines has so far been quite small 
despite the remarkable increase in their use in both 
developed and developing countries.
From a clinical pharmacologist’s perspective there 
are several issues surrounding traditional remedies. 
Preparation from natural ingredients plant, animal or 
mineral, is not necessarily standardised and quality 
may vary between suppliers and seasons. safety of 
traditional medicines cannot be taken for granted 
and several have demonstrated significant toxicity 
even after many years of use, e.g., nephrotoxicity 
and carcinogenicity of Aristolochia found in some 
traditional chinese preparations (82). many of the 
claims for efficacy have not been substantiated in 
adequate clinical trials although the spectacular anti-
malarial activity of medicines derived from Artemisia 
species should caution against dismissing activity 
until the evidence has been fully investigated. 
moreover, the taking of traditional and conventional 
medicines together predisposes to potential adverse 
interactions, e.g., the co-administration of st John’s 
wort (an enzyme inducer) may reduce the efficacy of 
medicines metabolised by the cytochrome P450 3a4 
enzyme sub-type (83).
all physicians need to be aware and knowledgeable 
about the side effects or toxicity of some common 
herbal remedies. Patients often use traditional 
medicines without being aware of the potential 
side effects or interactions with their other current 
medications, and fail to disclose this to their 
physician. In fact, it is up to the physician to be 
proactive by inquiring about the use of traditional 
medicines. In one report, approximately 20% of 
hospitalised patients used traditional medicines 
concurrently with conventional medicines without 
informing their physicians (84). the reasons for 
non-disclosure included patients’ anticipation of 
the physician’s disinterest or negative response, a 
misconception that the physician would be reluctant 
or unable to contribute useful information, and 
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complete ignorance of the potential risk of using 
traditional with conventional medicines (85).
It is clear from these observations that the training 
of clinical pharmacologists, and indeed of all 
physicians, needs to be reviewed to ensure that 
traditional medicines are included.
I  tHe UndergradUate medIcal 
cUrrIcUlUm
there is a need for instruction about traditional 
medicines at some point in all undergraduate medical 
curricula. this should provide an understanding of 
the commoner traditional medicines that are used in 
the particular society and that are therapeutically or 
toxicologically important in patient care. the aim is 
to enable the young doctor to advise and/or manage 
patients using these medicines, and to be vigilant 
for any potential interaction with conventional 
medicines. also, an opportunity to engage students 
in research involving traditional medicines might 
stimulate some to pursue working in this field at a 
later stage.
I  tHe PostgradUate clInIcal 
PHarmacologY cUrrIcUlUm 
Research: It would be appropriate to provide 
training in clinical research and evaluation of one 
or more of the common traditional medicines in 
the community for quality, safety and efficacy, using 
scientifically acceptable guidelines for conduct and 
evaluation of human studies.
Service: adequate instruction is needed to ensure 
that the clinical pharmacologist is competent to 
advise on the value, potential risk and management 
of patients using traditional medicines. However, to 
have a broader influence on prescribing by traditional 
healers or practitioners, it is desirable that the 
clinical pharmacologist undertakes further training 
in traditional medicine or even becomes a fulltime 
traditional medicine practitioner with specialisation 
in the clinical pharmacology of these medicines- 
though at present this would be a rare occurrence.
I resoUrces
In recent years, there has been a rapid expansion 
of evidence-based texts about traditional medicines 
(86-88) and the scientific basis for these preparations 
will continue to be strengthened. the cochrane 
library contains many systematic reviews of efficacy 
of traditional medicines (89) and several excellent 
websites provide information with its accompanying 
evidence (90-93). clinical pharmacologists should be 
aware of, use and promote these resources.
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the rise in clinical pharmacology in the 1960s 
was in a large part due to the realisation of basic 
pharmacologists that their discipline was too far 
removed from the practice of medicine, but also 
due to the desire of prominent clinicians specialising 
in pharmacotherapy to develop their science 
and improve the quality of drug therapy. clinical 
pharmacologists at the time had to have fruitful 
collaboration with both pharmacology and internal 
medicine and usually had considerable training in 
both disciplines.
clinical pharmacology at its best now requires a much 
broader view of all aspects of medicine in which 
drugs are used be it internal medicine, paediatrics, 
psychiatry, anaesthesiology, geriatric medicine or 
oncology. the role of clinical pharmacology in all 
these areas should be to educate physicians, to 
perform collaborative research and to disseminate 
information about the principles of drug evaluation 
and rUm. these roles are facilitated by having 
access to diversified methods for monitoring and 
improving drug therapy. as the field has evolved 
and clinical pharmacists and Ph.d. scientists 
trained in clinical pharmacology have increased in 
numbers, contribution and collaboration among 
these somewhat differently trained individuals 
has strengthened and extended the contribution 
of medically trained clinical pharmacologists. 
this is particularly the case for multi-disciplinary 
drug and therapeutics committees and drug 
information services. In pharmacoepidemiology 
and pharmacovigilance, collaboration with 
epidemiologists is necessary.
In tdm, collaboration with drug analytical experts 
is vitally important to maintain accreditation of the 
analytical methods used. such experts are usually 
trained in chemistry or pharmacy. collaboration 
with persons knowledgeable in molecular 
biology is of increasing importance, particularly in 
pharmacogenetics. many clinical pharmacologists 
depend on their collaboration with trained nurses 
who fulfil valuable roles in areas such as drug 
utilization measurement and evaluation and assisting 
with clinical trials.
15collaboration with other drug experts
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I  IntrodUctIon 
Historically, clinical pharmacology developed 
either from departments of pharmacology or 
from departments of internal medicine. clinical 
pharmacology is now an independent medical 
specialty in many countries. In countries where 
it is not a separate medical specialty, clinical 
pharmacology should be recognised as a scientific 
and clinical discipline in its own right. clinical 
pharmacology is usually organised in separate units 
headed by a clinical pharmacologist. depending 
on local and national circumstances, the unit could 
either be a division of clinical pharmacology in a 
clinical or in a pharmacology department. while 
internal medicine is historically the base clinical 
department, increasingly clinical pharmacology units 
are developing from other clinical specialties such as 
paediatrics (see chapter 7), geriatrics,(see chapter 8), 
anaesthesiology or psychiatry. 
Irrespective of which model is used, the optimal 
setting is in a university hospital as it supports all 
three major functions of clinical pharmacology: 
health care, teaching and research. county (or 
district) hospitals and primary health care also need 
experts in clinical pharmacology. such expertise can 
be provided from the university hospital if the local 
availability of clinical pharmacologists is limited. In 
some cases, the discipline of clinical pharmacology 
may justify only a small organisation and here the 
terminology of ‘Unit’ may be more appropriate than 
‘division’. there are several models of organisation, 
described below.
I  IndePendent dePartment oF 
clInIcal PHarmacologY In a 
UnIVersItY HosPItal
In some countries, clinical pharmacology has 
developed to such an extent that a separate 
department in a university hospital has been 
created. such departments have sufficient staff for 
the manifold interests of clinical pharmacology in 
research, teaching and clinical service. such staff 
will comprise both clinical pharmacologists and 
other multidisciplinary staff such as pharmacists 
and drug analytical staff and will often include basic 
pharmacologists.
the department may have beds, and the physician 
clinical pharmacologists are then fully responsible 
for the treatment of patients. the advantage of 
this arrangement is that the physician clinical 
pharmacologist is fully integrated in the clinical work 
of the hospital making it easier for them to relate 
to clinical colleagues. the disadvantage is that the 
involvement of physician clinical pharmacologists in 
direct health care will reduce their time availability 
for other important clinical pharmacology activities 
(see chapter 6). thus, in many countries, physician 
clinical pharmacologists are not directly responsible 
for patient care. as there are advantages and 
disadvantages in both models (see above) the 
model chosen should reflect the national and local 
traditions, circumstances and needs.
collaboration between basic and clinical pharma-
cologists enables achievements to be made that are 
rare when the disciplines work on their own. Finally, 
the department will need staff with other skills such 
as nurses, computer experts, statisticians, laboratory 
technicians and secretaries to fulfil its role properly.
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I  dIVIsIon or UnIt oF clInIcal 
PHarmacologY In a clInIcal 
dePartment
In many countries, this model for clinical 
pharmacology is more appropriate. It is likely to be 
the pattern where it is impractical to have a fully 
independent department and this is the model most 
likely to be relevant in resource poor environments. 
this may be the case where the range of clinical 
services required is significantly smaller than as listed 
in chapter 6 or where the number of staff employed 
only permits the provision of a limited range of such 
services. In either case, the long-term aim should 
be to grow so that a full range of services, relevant 
to the needs of the community, can be provided. 
this may result in the creation of an independent 
department in due course.
I  dIVIsIon or UnIt oF clInIcal 
PHarmacologY In a 
PHarmacologY dePartment 
In some cases, a clinical pharmacology unit (or 
division) has been organised in close association 
with (or has developed from) a department of 
basic pharmacology. the advantages of such an 
arrangement have been discussed above. there 
will be a considerable disadvantage if the basic 
pharmacology department is sited some distance 
from the hospital.
I  deVeloPment oF clInIcal 
PHarmacologY organIzatIons 
many clinical pharmacology organisations start 
small, but as they grow over the years in response 
to the healthcare needs of their communities, they 
develop new skills and require different staff groups. 
thus, there are examples of clinical pharmacology 
organisations that have developed from basic 
pharmacology but now have individual clinical 
pharmacologists who provide direct or consultative 
health care to patients, e.g. by looking after 
patients who have taken a drug overdose, running 
a unit for clinical trials, or evaluating patients with 
pharmacotherapeutic problems such as therapeutic 
failure or adrs.
equally, there are clinical pharmacology organisations 
that have developed from providing direct patient 
care to become more involved in the basic science 
of pharmacology – for example the use of molecular 
biology skills to understand pharmacogenetic 
variability and thereby to provide a more personalised 
approach to drug therapy. the training available 
for clinical pharmacologists will need to reflect this 
changing world (see addendum II).
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I  BackgroUnd
since the first edition of the wHo technical report 
in 1970 (1), the medical world has changed 
dramatically. new diseases have arisen (HIV⁄aIds), 
developments in molecular biology have generated 
new biotherapeutic agents, communications have 
been revolutionised by the Internet and many of 
the historically important diseases of the developing 
world are receding and being replaced by non-
communicable disease – with the notable exceptions 
of malaria and multidrug- resistant tuberculosis.
However, more than 50% of countries that replied 
to a wHo survey in 2003 had no policies in place to 
improve the use of medicines despite data showing 
around 50% of all medicines worldwide are being 
used inappropriately (38.) a prominent example is 
the excessive use of antibiotics which is a major factor 
in the high prevalence of resistance to previously 
first-line antibiotics for dysentery, pneumococcal 
pneumonia and hospital-acquired infections (38). 
the world Health assembly, recognising these 
problems, urged ‘member states to establish or 
strengthen multidisciplinary national bodies for 
monitoring medicine use, and to implement national 
programmes for the rational use of medicines’ (wHa 
resolution 60.16, may 2007).
with this as background, it can be argued that 
the most important single development that has 
expanded the role of clinical pharmacologists in 
global public health has been the recognition by 
many developed and developing countries of the 
value of a national medicines Policy. the initiative 
came to a focus in the wHo ‘guidelines for the 
development of national drug Policies’ published in 
1988 (2). more than 150 countries now have their 
own policies in varying stages of implementation. 
these policies aim to ensure:
• the quality, safety and efficacy of medicines
• equitable access to medicines for all the population
• the rational ⁄ quality use of medicines
•  ‘a viable and responsible local pharmaceutical 
industry’ (quotation from the australian national 
medicines Policy, 2000). clinical pharmacologists 
have clear and demanding roles in the 
implementation of each of these key ingredients. 
I  QUalItY, saFetY and eFFIcacY oF 
medIcInes
Quality of medicines is threatened by counterfeiting, 
poor manufacturing practice or the unscrupulous 
marketing of time-expired products – each of 
these is a contemporary problem, especially in the 
developing world (94). In many countries, clinical 
pharmacologists contribute substantially to drug 
regulation. the pre-marketing assessment of the 
quality, safety and efficacy of a new medicine 
demands critical skills possessed by the trained 
clinical pharmacologist, including a capacity to 
evaluate clinical trials performed in many different 
clinical areas. the ability to assess the relevance and 
possible problems of a new medicine for a particular 
population also requires an understanding of local 
epidemiology (if only to establish whether or not 
the country ‘needs’ this particular medicine – based 
on an assessment of the prevalence and severity 
of any particular medical condition) and possible 
racial variations in, for example, the metabolism of 
medicines.
Increasingly, pharmaceutical companies are 
conducting clinical trials in developing countries in 
17the central Place of clinical Pharmacology in global Public Health
Clinical Pharmacology in Health Care, Teaching  and Research48
the expectation that this will be a cost- and time-
efficient way of recruiting large numbers of patients. 
the trial results feed into the regulatory system at 
the point of pre-marketing assessment. clearly, this 
provides an opportunity to obtain country-specific 
data, but it also raises the question of who takes 
clinical responsibility for critically assessing trial 
protocols, who manages the necessary initial research 
ethics application and clearance, and who takes 
responsibility for the clinical supervision of patients. 
these are standard roles for clinical pharmacologists 
in developed countries and there is a strong case for 
providing positions in less developed countries for 
the same purposes.
safety cannot be fully appraised at the point of 
marketing and only some form of post-marketing 
surveillance will permit the timely detection of less 
common adverse effects not detected in the limited 
pre-marketing data. For many developing countries, 
limited resources mean that most new medicines 
approved for marketing have already been used for 
years elsewhere, and there is a greater probability 
that their safety has been more fully characterised, 
allowing for differences in pharmacogenetic 
variations from country to country. In whichever 
context, the clinical pharmacologist has a major role 
in the setting up of spontaneous reporting systems, 
in reviewing (and suggesting action on) reported 
adverse events, and in providing data not only to 
guide decisions in the home country but also to 
contribute to the global database (95).
I  eQUItaBle access
the individual’s right to the ‘best possible standard 
of health’ is set out in the Universal declaration of 
Human rights (96). when challenged in the courts 
of several countries, the right of access to essential 
medicines has been upheld as an extension of the 
right to health (97). despite this assertion of principle 
and intent, wHo estimates that as many as two 
billion people worldwide do not currently have access 
to essential medicines. For the poorest populations, 
lack of finances may be the major cause. an estimate 
of annual per capita income adjusted for within-
country cost of living, expressed in ‘international 
dollars’ (so-called ‘‘Purchasing Power Parities’’) was 
$41,674 for the United states in 2005, $3487 for sri 
lanka and $1892 for nigeria (98). with no regular 
acceptance of the need for medicine prices to be 
proportional in some measure to national per capita 
income, the costs of many medicines are beyond 
the limited resources of the poorer countries as the 
figures above predict.
many countries have or are developing systems 
for pre-marketing economic evaluation of 
medicines. while the economic model chosen will 
influence the outcome, the starting point is always 
evaluation of the clinical trials data from which 
the estimate of potential benefit is derived, to set 
alongside cost in the cost-effectiveness calculation. 
this requires clinical pharmacological skills and 
involvement of clinical pharmacologists as part of 
the pharmacoeconomic team to address these issues 
specifically. In countries where the cost of medicines 
to the individual is subsidised by government, a list 
of selected medicines is maintained.
this may be the same as the country’s ‘essential 
medicines list’, and this is the case in many low 
and middle income countries. However, subsidy of 
this type – whether funded entirely by government, 
partly by the patient as a co-payment or through 
some form of insurance scheme – requires a rigorous 
examination of not only the quality, safety and 
efficacy of medicines but also measures of cost-
effectiveness and affordability.
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clinical pharmacologists are commonly involved in 
this selection process in developed countries but 
much less so at present in the developing world, 
partly because there are so few of them. Buying 
only medicines that are cost-effective and affordable 
locally is a potent way of ensuring that limited 
resources are used to best advantage.
I  ratIonal Use oF medIcInes
Having medicines of high quality that are accessible 
to all does not guarantee that they will be used in 
the best possible way. more money can be saved 
and health objectives met by ensuring the highest 
standard of use. over the past two decades, methods 
for measuring and evaluating the quality of use of 
medicines have been developed and implemented.
Drug utilisation reviews
one of the first steps in improving the way medicines 
are used in any community is definition of the 
potential or actual problems. measuring medicine use 
and relating it to clinical indication in a community, 
hospital, clinic or at a national level is not the easy 
task it would be if there were databases that could 
be linked (with proper attention to confidentiality of 
the records). supply is not the same as utilisation, 
although in some circumstances, especially in 
resource-poor settings, it may be the only surrogate 
available. commonly, utilisation has to be measured 
prospectively by data collection in a defined area for 
an adequate time, to ensure representative results. 
In many countries, this task has fallen to pharmacists 
who have had special training in the methods. 
However, when the results are being interpreted, 
clinical input is required. clinicians with specialty 
training are needed in order to judge whether 
prescribing has been appropriate. Ideally this role is 
best filled by a clinical pharmacologist with broad 
clinical training and experience. standard treatment 
guidelines (below) that have been endorsed for a 
country, hospital or community serve as the reference 
standard and help to define inappropriate practice. 
the clinical pharmacologist should be a member 
of the evaluating team and also in the design and 
implementation of interventions to mitigate problems 
that are identified.
Standard treatment guidelines
the introduction of evidence-based treatment 
guidelines is one of the interventions that has a large 
potential to improve the quality of use of medicines 
(99). to have the necessary authority, the guidelines 
should contain the best available evidence, be put 
together with representative input from all end-users 
and be sensitive to local conditions (e.g. storage 
and transport problems for particular formulations of 
medicines in remote countries with difficult climates 
such as the isolated island communities of the Pacific 
region). the guidelines should also be endorsed by 
local opinion leaders (including government and 
professional associations) and be revised regularly 
to maintain currency. clinical pharmacologists 
commonly have a central role in developing 
guidelines and their broad training fits them for this 
task.
Essential medicines lists
the essential medicines list should reflect, and derive 
from, the national standard treatment guidelines. 
Ideally, guidelines should be prepared first and 
the essential medicines list produced from their 
recommendations. whatever the sequence, the two 
documents should always be harmonised at each 
updating and review.
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Objective information about medicines 
(see also chapter 6)
In many developing countries, there is a dearth of 
objective information for health professionals about 
medicines, the gap being filled by information 
provided by pharmaceutical companies with, 
not unexpectedly, a promotional bias. many 
developed and some developing countries produce 
regular drug information journals. these deal with 
topical issues about the use of medicines, review 
the profiles of newly introduced medicines and 
discuss adverse effects. clinical pharmacologists 
play a major role in the editorial processes and as 
authors for such publications. In some developed 
countries, drug information centres staffed by 
clinical pharmacologists, pharmacists and other 
health professionals have been set up to provide 
patient-focused information. Increasingly, medicines 
information is being produced for consumers, written 
in non-technical language and in some countries 
issued with all first prescriptions for medicines.
Education of health professionals and of 
consumers (see also chapter 9 and addenda I and II)
clinical pharmacologists working within the 
health system always have a responsibility to be 
involved in undergraduate, postgraduate and 
continuing education. much evidence suggests that 
doctors prescribe less well than they might (6,38). 
Undergraduate training, with continuation into post-
graduate and continuing education, has the potential 
to lift the level of prescribing beyond the mediocre 
and provide a pattern for life-long learning as new 
medicines, or new uses for old ones, are introduced.
whose business is the education of consumers? Peer 
education is a powerful technique and several studies 
have demonstrated its effectiveness in improving 
understanding and use of medicines. If this is the 
strategy chosen, the clinical pharmacologist may 
not be the primary educator but often becomes 
the adviser who helps to translate the information 
from medical to everyday language. work in a drug 
Information centre and drug and therapeutics 
committees may be a natural extension of the tasks 
listed above – especially in larger teaching hospitals.
I  tHe clInIcal PHarmacologIst’s 
JoB descrIPtIon For gloBal 
PUBlIc HealtH
there is a wide ‘job description’ for the clinical 
pharmacologist working predominantly in the health 
system. It is good that we can now demonstrate 
that many of the strategies listed above have 
strong evidence that they are effective in increasing 
knowledge, improving prescribing or the consumer’s 
use of medicines (99). However, while it appears 
intuitive, there is virtually no evidence to link 
improved prescribing and use of medicines uniquely 
to improved health outcomes although there is 
the honourable exception of improved compliance 
⁄ adherence, reflected in better disease control – 
especially most recently in the treatment of HIV⁄aIds 
– and some instances where antibiotic choice and 
adherence play the crucial role in patient recovery. 
the list of tasks above (and in chapter 6) reflects the 
clinical pharmacologist’s usual pre-occupation with 
prescription medicines. a further, emerging role is 
in the evaluation and investigation of traditional 
medicines (see chapter 14) which provide first-line 
treatment for up to 80% of the world’s population. 
largely neglected by western clinical pharmacology, 
these traditional preparations have the potential to 
provide surprises. For example, it is arguable that the 
most important advance in the pharmacotherapy of 
malaria in the last decade has been the introduction 
of the Artemisia derivatives – which come directly 
from the chinese herbal tradition.
several developed and developing nations 
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have recently set up a regulatory framework for 
traditional ⁄ complementary medicines. the concerns 
that prompted these initiatives were the need to 
ensure quality control in the manufacture of these 
products and to evaluate the potential for unexpected 
toxicity (as demonstrated, for example, by aristolochic 
acids in some traditional medicines as a cause of 
renal impairment and renal cancer (82)). there is 
also the difficult problem of assessing the efficacy of 
products that have had little or no scientific study in 
the past, and which are produced by an industry that 
has only limited options for patent protection. 
In addition, there are only limited funds available 
for the necessary clinical trials work and thus many 
problems remain to be solved. However, research 
money is beginning to flow from both pharmaceutical 
companies and from government sources in some 
countries.
In several instances, clinical pharmacologists have 
been members of the national advisory committees 
making recommendations to government regulators, 
and in both australia and the Uk these committees 
have been chaired by a clinical pharmacologist. 
some preparations that have been in use for many 
centuries warrant investigation and evaluation – a 
further role for the clinical pharmacologist in relation 
to global health.
the recognition that medicines are used for 
treatment or prophylaxis on such a scale in many 
populations that they assume the same importance 
as other factors that influence public health has led 
to the use of epidemiological methods to explore 
the impact of medicines on populations as a whole. 
the exploration of adrs has led to fresh approaches 
for the linkage of events with medicines use. case–
control studies (100) and health database linkage 
have raised hypotheses, and sometimes provided 
hard causality evidence about events stemming 
from drug exposure. record linkage is at present 
only feasible in countries that have the necessary 
accessible databases but will undoubtedly spread 
more widely as the technology comes within the 
reach of less well resourced countries.
I  conclUsIons
the discipline of clinical pharmacology arose from the 
two imperatives of the need to be able to measure 
the efficacy of medicines in patients and the equally 
urgent need to be able to monitor adverse effects. 
However, the list of ingredients in a contemporary 
clinical pharmacologist’s work provides a menu too 
full for a single individual. In reality, and especially 
in resource-poor countries, clinical pharmacologists 
will make the biggest contribution, working as part 
of a team, whether in the hospital, the community 
or in an administrative position. training of clinical 
pharmacologists to meet these needs will have to 
be rather different and much broader than envisaged 
in 1970. It is covered in chapter 9 and in addenda 
I and II.
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I  cHaPter 3. tHe deFInItIon oF 
clInIcal PHarmacologY
clinical Pharmacology is the scientific discipline that 
involves all aspects of the relationship between 
drugs and humans and involves the delivery of 
health care, teaching and research as well as helping 
to frame policy and giving information and advice 
about drugs. It is a multidisciplinary science that 
encompasses professionals with a wide variety of 
scientific skills including medicine, pharmacology, 
pharmacy, biomedical science and nursing. the 
term ‘clinical pharmacologist’ is also used in the 
professional sense to refer to those physicians 
who are specialists in clinical pharmacology. 
they have usually undertaken several years of 
postgraduate training focussing on important 
aspects of clinical pharmacology including clinical 
trials, drug evaluations, pharmaco-epidemiology, 
pharmacoeconomics, pharmacogenetics, pharma-
covigilance and clinical drug toxicology. the primary 
goal of clinical pharmacologists is the improvement 
of patient care, directly or indirectly, by promoting 
the safer and more effective use of drugs. 
I  cHaPter 4. tHe HIstorY oF 
clInIcal PHarmacologY
clinical Pharmacology is a relatively new medical 
discipline having been developed extensively in 
the middle of the 20th century. However it has its 
roots in a much older tradition of ‘materia medica’ 
going back for centuries. after a period at the end 
of the 20th century when the discipline was seen to 
contract in some countries there are now new signs 
of optimism (see introduction).
overview
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I  cHaPter 5. tHe gloBal medIcIne 
scene –tHe Place oF clInIcal 
PHarmacologY
modern drug therapy has unquestionably improved 
the health of peoples in developed countries over 
the last 50 years and yet there is much more that 
could be done in these countries quite apart from the 
needs of developing and resource poor countries.
I  cHaPter 6. tHe clInIcal 
PHarmacologIst In PatIent 
care
the prime function of a clinical pharmacologist 
in patient care is to deliver safe and effective drug 
therapy in what is often termed the rational Use 
of medicines (rUm). In some cases this is done 
directly where a clinical pharmacologist has direct 
responsibility for patient care, but more commonly 
a range of services is offered to clinical colleagues 
and their patients. clinical pharmacologists are 
trained particularly in the critical evaluation of both 
new and old therapies and so may function on drug 
and therapeutic committees or by delivering drug 
information services (often in collaboration with 
other health care professionals such as pharmacists). 
special skills are available in drug utilisation, 
pharmacoepidemiology, and pharmacovigilance. In 
addition many clinical pharmacologists are involved 
in therapeutic drug monitoring services. these are 
often combined with pharmacogenetic services 
leading to a personalised medicine approach which 
can result in more effective therapy with fewer 
adverse drug reactions.
overview 18
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I  cHaPter 7. drUg tHeraPY In 
PaedIatrIc PatIents
the treatment of paediatric patients needs special 
skills since children are not just small adults. after a 
number of drug disasters in children in the 1950’s it 
was recognised that paediatric clinical pharmacology 
was a specialty in its own right which needed 
development for a number of reasons but particularly 
because of the high death rate of children from 
treatable diseases in under-developed countries.
I  cHaPter 8. drUg tHeraPY In 
gerIatrIc PatIents
the treatment of elderly patients is a real concern 
in today’s world. the most rapidly expanding age 
group in the world is the over 80 age group. elderly 
patients have particular problems in drug therapy 
as increasing age is associated with impairment of 
several physiological functions particularly renal 
function which affects the excretion of drugs and their 
metabolites. In addition therapy with multiple drugs 
leads to more problems from drug interactions. thus 
some specialists in the care of the elderly patients 
have developed special skills in geriatric clinical 
Pharmacology. 
I  cHaPter 9. teacHIng clInIcal 
PHarmacologY
all clinical pharmacologists have a considerable 
role to play in teaching, whether this is at the 
undergraduate, postgraduate or continuing 
professional development level. most attention is 
currently directed at the undergraduate medical level 
because of the increasing demands being placed on 
new prescribers and because of the evidence that 
new prescribers are more likely to prescribe less 
effectively and with more errors than their seniors. 
a number of different approaches to this problem 
are described and in a comprehensive addendum 
(addendum I) a model approach to the required core 
knowledge and Understandings, skills and attitudes 
is suggested.
Postgraduate teaching of clinical Pharmacology is 
also covered (see chapters 9 and 12 and addendum 
II) but the approach here is a more general one 
mostly because there is far greater variability in the 
availability of staff and resources as well as more 
varying needs around the world in the postgraduate 
scene than in the undergraduate one.
I  cHaPter 10. researcH domaIns 
oF clInIcal PHarmacologY
research is a fundamental part of the training and 
the work of virtually all clinical pharmacologists. the 
endeavour of a pharmacologist working in a clinical 
environment is to develop methods and strategies 
that improve the quality of drug use in individual 
patients and patient populations. research in drug 
evaluation, drug utilisation, pharmacovigilance 
and pharmacoepidemiology has become more 
important than at the time of the 1970 wHo 
report (1).  the rational Use of medicines (rUm) 
implies that drugs should be chosen according to 
their efficacy, adverse drug reactions and cost as 
potentially equally important parameters. research 
in clinical pharmacology includes studies that 
elicit new data about drugs in use such as new 
indications and treatment in neglected populations. 
It also includes research on adverse drug reactions, 
pharmacogenetics and drug interactions. research 
in clinical pharmacology is almost always 
multidisciplinary. 
Clinical Pharmacology in Health Care, Teaching  and Research 55
I  cHaPter 11. emergIng roles 
oF clInIcal PHarmacologY: 
tHe examPle oF BIologIcs and 
BIosImIlars
Biologicals play an emerging role in clinical 
pharmacology. In contrast to common drugs, 
which are typically manufactured through chemical 
synthesis, biologics are made in a living system, 
so the usual generic approach is scientifically not 
appropriate for these products. Biosimilars require 
a special regulatory framework in order to ensure 
that biological therapies are safe and effective, and 
require post-marketing monitoring similar to that for 
new innovative biologics. Hence the assessment of 
the harm/benefit ratio of biologics and biosimilars 
is a challenge for physicians, manufacturers and 
regulatory authorities and requires expertise across 
multiple disciplines.
I  cHaPter 12. clInIcal 
PHarmacologY and tHe 
PHarmaceUtIcal IndUstrY
the clinical pharmacologist has much to offer 
the pharmaceutical and biotechnology industry 
at all levels. the clinical pharmacologist’s broad 
knowledge of all aspects of drug use combined with 
the insights gained from clinical practice provides a 
unique platform to influence the effective and ethical 
development and marketing of therapeutic drugs. 
clinical pharmacologists contribute at many levels 
from broad high level management positions to a 
focus on a special area of expertise within clinical 
pharmacology. they develop a range of skills and 
knowledge not often encountered in academic 
clinical pharmacology.
I  cHaPter 13. goVernments: 
essentIal roles For clInIcal 
PHarmacologY
governments need to develop systems to serve the 
public by ensuring that only safe and effective drugs 
are authorised for use in their populations and the 
clinical pharmacologist is well suited to this purpose 
as well as facilitating cost effective prescribing 
and improving the rational use of medicines. the 
training of clinical pharmacologists is ideal to meet 
the needs of various government services in order 
to ensure that the best scientific knowledge is used 
in making decisions in public health. In particular, 
the governments of emerging economies and 
developing countries could benefit from the expertise 
of clinical pharmacologists, although few have given 
the necessary priority to the development of the 
discipline and many would have difficulty in creating 
positions that are seen to compete for funds with 
other medical disciplines. 
I  cHaPter 14 . tHe clInIcal 
PHarmacologIst and 
tradItIonal medIcInes
clinical pharmacologists conventionally have had 
little exposure to traditional medicines and yet 
these are widely used both in the developed and 
in the under-developed world. It is clear that use 
of traditional medicines can cause harm as well as 
benefits. clinical pharmacologists should be better 
informed about traditional medicines and be more 
involved in work to increase the scientific knowledge 
around traditional medicines.
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I  cHaPter 15. collaBoratIon 
wItH otHer drUg exPerts
clinical pharmacology is a multidisciplinary activity 
and close working relationships with a number of 
different professional groups is critical. some of the 
disciplines involved in various aspects of clinical 
pharmacology include medicine, pharmacology, 
pharmacy, biomedical science, nursing, social 
and behavioural sciences, dentistry, economy, 
epidemiology, genetics, toxicology, mathematics and 
computer sciences.  
I  cHaPter 16. organIsatIon: 
strUctUral models For clInIcal 
PHarmacologY
clinical pharmacology services can be delivered 
through a variety of different organisational 
arrangements. there is little doubt that the most 
effective system is for the clinical pharmacology 
services to be delivered from a department or division 
based within a hospital, whether the hospital is a 
university hospital or a district general hospital. the 
needs of primary care are also important particularly 
where these services are delivered outside the 
hospital setting.
 
I  cHaPter 17. tHe central Place 
oF clInIcal PHarmacologY In 
gloBal PUBlIc HealtH
the development of clinical pharmacology has 
been centred on the ‘developed’ countries of the 
world and yet the needs are arguably greater in the 
developing and resource poor countries. the skills 
and resources available in such countries necessitate 
a different approach to developing the rational use 
of medicines. the discipline of clinical pharmacology 
arose from the two imperatives of the need to 
measure the efficacy of medicines in patients, and 
the need to be able to monitor therapy and prevent 
adverse drug effects. However the list of ingredients 
in a contemporary clinical pharmacologist’s work 
provides a menu that is too full for a single individual 
or discipline. In reality, and especially in resource poor 
countries, clinical pharmacologists make the biggest 
contribution, working as part of a team, whether in 
the hospital, the community or in an administrative 
position.
training of clinical pharmacologists to meet these 
needs is rather different, and much broader, than 
envisaged in 1970 when the initial wHo report was 
published (1).
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this addendum provides a list of knowledge and 
understanding, skills and attitudes relevant to the 
use of drugs that should be core content in the 
undergraduate medical curriculum. these represent 
key learning outcomes that will enable all graduates 
to prescribe safely and effectively at the point of 
graduation. these core objectives are generic and 
applicable to most areas of therapeutics. they 
should be considered in association with a relevant 
list of core drugs and therapeutic problems to which 
they apply. medical schools should be encouraged 
to identify lists that are appropriate for their local 
circumstances. For each drug, graduates should be 
expected to have an understanding of the mechanism 
of action, recognise the appropriate indications for 
use, know the appropriate route(s) of administration, 
and know the important contra-indications and 
adverse effects. In some cases a drug class is listed 
with a commonly used member of the class as an 
example. the list of drugs chosen might be viewed 
as a ‘student formulary’. 
I  core knowledge and 
UnderstandIng, skIlls and 
attItUdes reQUIred to sUPPort 
ratIonal PrescrIBIng 
Core Knowledge and Understanding
Basic pharmacology 
•  the general mechanisms of action of drugs at a 
molecular, cellular, tissue and organ level 
•  the ways in which these actions produce 
therapeutic and adverse effects
•  the receptor as a target of drug action and related 
concepts such as agonism, antagonism, partial 
agonism and selectivity
• the development of tolerance to drugs
clinical pharmacokinetics 
•  the mechanisms of drug absorption, distribution, 
metabolism and excretion
•  the concepts of volume of distribution, clearance 
and half-life and their clinical relevance
•  how these factors determine the optimal 
route, dose, frequency, and duration of drug 
administration
Factors that determine inter-individual variation in 
drug response
• adherence to therapy
• pharmacodynamic variation
• pharmacokinetic variation
• pharmacogenetic variation
• environmental variation
• pharmaceutical variation
monitoring drug therapy
•  the importance of monitoring the effect of drug 
therapy
•  the ways in which this can be achieved (e.g. 
measuring plasma drug concentrations or 
assessing pharmacodynamic responses)
 •  the variable relationship between drug dose, 
plasma concentration and clinical effect
adverse drug reactions 
• the different types of adverse drug reactions
•  the frequency of adverse reactions in primary and 
secondary care
•  recognition of common susceptibility factors and 
how risks of harms can be minimised
•  the importance of reporting adverse reactions and 
other approaches to pharmacovigilance
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drug-drug interactions
•  the potential for drugs to interact to cause 
beneficial and harmful effects
•  the mechanisms by which drugs interact 
(pharmaceutical, pharmacokinetic, pharmacodynamic)
•  the ways in which interactions can be predicted 
and avoided
medication errors 
• the different types of medication errors
•  the common reasons medication errors occur in 
practice 
•  the ways in which individual prescribers can 
reduce the risk of medication errors
clinical drug toxicology
•  the assessment, recognition and treatment of 
common intoxications (e.g. paracetamol)
•  the principles of removing or counteracting the 
effects of toxic substances after ingestion
• toxicokinetics and toxicodynamics
Prescribing for special patient groups with altered 
physiology, pharmacokinetic handling and 
pharmacodynamic responses 
• elderly patients    
• children
•  women who are pregnant, breast-feeding, or of 
child-bearing potential
• patients with renal or liver disease
legal aspects of prescribing drugs
•  categorisation of drugs as over-the-counter 
preparations, prescription-only medicines, 
controlled drugs
•  the prescribing of ‘unlicensed’ preparations
•  the responsibilities associated with prescribing 
controlled drugs
developing new drugs
•  drug development including clinical trials (Phase I 
to Phase IV) 
•  the approval process and major regulatory 
authorities in the relevant country
• the requirements of good clinical trial design 
•  consent, ethics, bias, statistics, dissemination of 
information
Understanding the principles and pitfalls of clinical 
drug trials
• aims of the trial
• relevance of the trial for health care
•  selection of patients, diagnostic criteria and 
sampling procedure, criteria for inclusion and 
exclusion
•  controls: crossover, separate control group, 
untreated, other therapy, placebo
• design: double blind, single blind, open
• randomisation of treatment
concentration-effect studies, biomarkers
• drug interaction
• recording of effects (subjective and/or objective)
• recording of adverse effects
• statistical planning
•  the author’s conclusion: adequate, questionable, 
irrelevant or impossible?
managing the prescribing of medicines in the health 
service
• the role of local formularies
• the role of drug & therapeutics committees
•  the influences that affect individual prescribing 
choices
•  the rational assessment of new drugs based on 
safety, efficacy and cost-effectiveness
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ethics of prescribing
• informed patient consent and adherence to therapy
commonly used drugs
•  the mechanism of action, the indications for use, 
the appropriate route, frequency and duration 
of administration, and the important contra-
indications and adverse effects of commonly used 
drugs 
common therapeutic problems
•  the management of common acute and chronic 
therapeutic problems 
alternative therapies and traditional medicines
•  the motivations that lead patients to seek 
alternative therapies
•  some common indications and appraisal of the 
evidence for their efficacy
•  how such therapies interact with prescription 
drugs that patients are receiving
drug information retrieval
•  retrieval of drug information for prescribers and 
other health care staff
•  acquisition of knowledge and practice in how to 
assess the value and reliability of drug information 
sources
 
Core Skills
taking a drug history
•  taking accurate information about current 
prescription and non-prescription drugs 
•  making an assessment of adherence to a 
medication regimen
•  recording current and past adverse drug reactions 
and allergies
Prescription writing 
•  choosing a safe and effective drug and an 
appropriate dose
•  writing accurate, legible, and legal prescriptions 
including controlled drugs
•  keeping accurate records of prescriptions and 
response
•  calculation of drug doses based on patient weight 
or a nomogram
•  calculation of the strength of an infusion based on 
the required rate of drug administration
•  prescribing oxygen (flow rate, delivery) and 
intravenous fluids
drug administration 
• selecting the appropriate route of administration
•  administering subcutaneous, intra-muscular and 
intravenous injections
•  preparing drugs for parenteral administration 
including mixing and dissolving drugs 
•  preparing and administering drugs by an infusion 
pump
•  preparing and administering nebulized drugs
•  advising patients about special modes of drug 
delivery e.g. inhaled, topical, insulin
Prescribing drugs in special groups
•  elderly, children, pregnancy and breast-feeding, 
renal and liver failure
Prescribing drugs to relieve pain and distress
• palliation of pain and other distressing symptoms
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adverse drug reactions and interactions
•  assessing drugs as a possible cause of symptoms 
and signs
•  recognising the potential for adverse interactions 
•  reporting adverse drug reactions and interactions
drug allergy 
•  recognising allergic drug reactions and taking a 
history of allergic reaction
•  treating allergic reactions, emergency treatment of 
acute anaphylaxis
clinical pharmacokinetics 
•  using core knowledge of pharmacokinetics to 
inform safe prescribing
monitoring drug therapy 
• identifying which therapeutic effect to observe
•  using measurements of plasma drug concentrations 
appropriately (which and when) 
•  acting appropriately with the results
analysing new evidence
• practising evidence-based prescribing 
•  assessing the validity of evidence presented on 
new drugs or therapies 
•  reading, assessing and criticising clinical studies
•  spotting methodological flaws including sources 
of bias
•  recognising the difference between clinical and 
surrogate end-points
obtaining accurate objective information to support 
safe and effective prescribing
• using national Formularies 
•  accessing reliable drug information from medical 
journals and medical databases
• accessing Poisons Information services
•  assessing the reliability of varying sources of 
evidence and opinion
obtaining informed consent to treatment
•  providing patients with enough information about 
drugs to allow them to make informed decisions 
about their treatment
•  discussing benefits and harms of drug therapy 
with the patients
•  exploring patients’ own views and wishes in 
relation to drug treatment
Core Attitudes
a rational approach to prescribing and therapeutics
• identifying the correct clinical diagnosis
•  understanding the pathophysiological processes 
involved
•  knowing the drugs that might beneficially influence 
these processes
•  establishing the end-points with which to monitor 
therapeutic response
•  assessing the potential harms and benefits of 
treatment
•  communicating with the patient in making the 
decision to treat
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assessing the balance of benefit to harm
•  recognising that there are harms and benefits 
associated with all drug treatments 
•  recognising these may differ between patients 
depending on a variety of factors
•  recognising that doctors should monitor the effects 
of the drugs they prescribe
recognising the responsibilities of a doctor as part of 
the prescribing community
•  avoidance of wasteful prescribing and consumption 
of limited resources
•  recognising the need to report adverse drug 
reactions for the common good
•  controlling the availability of restricted drugs
•  adhering to therapeutic guidelines and drug 
formularies as appropriate
•  avoidance of indiscriminate prescribing of 
antibiotics 
recognising personal limitations in knowledge
•  recognising the need to seek further information 
about drugs when faced with unfamiliar 
prescribing problems
responding to the future
•  recognising the need to update prescribing 
practices
•  ensuring that patients benefit when possible from 
advances in medical knowledge
•  recognising the need to assess the benefits and 
harms of new therapies
•  knowing the limitations of applying clinical trial 
data to individual patients
recognising the effect of drugs on the environment
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I  IntrodUctIon 
a medical clinical pharmacologist is a physician with 
an advanced knowledge of pharmacology and the 
skills needed to achieve the rational use of medicines 
(rUm) in individual patients and in the population 
at large. the former may include the direct care of 
patients and also includes consultations on patients 
with complex drug problems such as therapeutic 
failure, adverse drug reactions and drug interactions. 
this pattern will vary from country to country. 
Improving drug therapeutics more broadly includes, 
but is not limited to, work on drug development, 
drug utilisation (both analysis of current practices 
and research on ways to improve it), teaching and 
providing information about drug therapy, working 
in drug and therapeutics committees from local 
(hospital formulary) to regional, national, and 
international organisations, and other problems that 
arise during the practice of clinical pharmacology 
(see below).
I  aIm
this model curriculum is designed to enable the 
aspiring clinical pharmacologist to obtain the 
knowledge and skills needed to carry out this 
professional activity in an efficient and satisfying 
way. It is deliberately set to be broadly based and 
thus applicable to as many countries as possible.
I  admIssIon reQUIrements
Physicians are usually admitted to a clinical 
pharmacology training program after they have 
completed the requirements for registration as a 
practising physician in their geographic area. In 
addition they will often have completed 2-3 years of 
work as a practising doctor under supervision in one 
of the specialties in which drug therapy is the major 
means of treatment.
However admission requirements will vary 
depending on national needs and agreements.
we recognise that the above scheme represents the 
ideal for the training of clinical pharmacologists but 
in many parts of the developing world it may be 
necessary, for practical reasons, to reduce the scope 
of the training in order to see health care delivered by 
health care professionals with a relevant knowledge 
of clinical pharmacology. other entry requirements 
in the form of preparatory/orientation training for 
general medical officers or general physicians are 
determined according to local conditions. 
I  otHer Interests
a physician starting the program after initial medical 
registration or licensure may wish to acquire 
additional specialty training. this can be interspersed 
with clinical pharmacology training by special 
arrangement with the directors of both programs or 
following the clinical pharmacology training. 
Syllabus Overview 
the formal clinical pharmacology training program 
is normally a 3 year activity but can vary from 2 – 
5 years depending on the country concerned. the 
activities include: 
1.  Formal instruction for the trainee to acquire 
the specialist fund of knowledge of a clinical 
pharmacologist which often involves working 
closely with basic pharmacology.
2.  clinical experience caring for patients with drug 
problems.
3.  research experience that advances therapeutics 
more broadly. In some countries cPt is a research 
intensive discipline entailing the production of a 
thesis.
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1. Formal instruction should include:
•  a review of the broad field of pharmacology 
including the topics covered in a medical school 
pharmacology course but at an appropriately high 
level. It is often of great benefit for the trainee to 
spend time in a basic pharmacology department 
and to experience work in such a laboratory 
including work with animals.
•  Pharmacological topics of special relevance to the 
discipline are:
i. critical evaluation of drug effects, both desired 
and adverse;
ii. Principles of research methods in humans, 
both experimental and observational ,eg 
clinical trials methods;
iii. Informed voluntary consent and ethics of 
research in humans; 
iv. data management and biostatistics;
v. absorption, distribution, metabolism and 
excretion (adme) of drugs in humans;
vi. Pharmacogenetics;
vii. additional sources of variation among people 
in their dose-response, such as age, gender, 
pregnancy, liver and renal disease, drug 
interactions and environmental factors;
viii. drug concentration measurement and 
techniques for monitoring drug therapy;
ix. drug intoxications and poisoning, both 
intentional and accidental;
x. drug tolerance, dependence and addiction;
xi. Pharmacovigilance and pharmacoepidemiology 
(including drug utilisation);
xii. Pharmacoeconomics;
xiii. the process of drug discovery, development and 
regulation;
xiv. adherence to medication regimens;
xv. drug information; 
xvi. other topics of local relevance.
the specific subject matter should be covered at the 
appropriate time in the complete curriculum.
 
2.  Clinical experience caring for patients with drug 
problems 
the trainee should get substantial clinical experience 
consulting about or caring for patients with serious or 
complex drug problems with increasing responsibility 
as the trainee’s knowledge and skill levels increase. 
Ideally, experience with infants and children as 
well as elderly patients should be included. this 
experience may be concentrated in one part of the 
program or spread throughout it.
3.  Research experience that enhances knowledge of 
drug therapy more broadly 
the trainee should be encouraged to identify, 
by the end of their first year of training, an area 
of drug therapy in which information could be 
improved, with benefit to future drug therapy. 
the trainee will then plan the research to be done, 
write the protocol, and obtain any necessary ethics 
committee approval for the work to proceed. 
this work will be done under supervision and the 
results reported in such a way that they can then be 
communicated to others, preferably by publication in 
a learned journal or monograph. trainees with talents 
in research should be encouraged to complete a Phd 
thesis (or equivalent) in clinical pharmacology.
this research experience has been discussed in the 
broadest terms and should be applicable anywhere. 
what is important is for the trainee to develop the 
attitude that gaining new knowledge to improve 
drug therapy for an identifiable group of patients, 
no matter how few in number or how small the 
geographic area in which these patients live, is part 
of the practice of clinical pharmacology.
Clinical Pharmacology in Health Care, Teaching  and Research 75
I  reQUIred traInIng resoUrces
a clinical pharmacology training program must 
have resources for the curriculum to be carried out. 
this requires an adequate number of trained and 
committed staff, a sufficient number of patients 
with a variety of illnesses for adequate clinical 
pharmacology experience for the trainee, supporting 
clinical services including the ability to measure 
concentrations of drugs in human body fluids, and 
research facilities for the resident to carry out a 
research project. 
a training program can be at a single institution with 
all the resources needed or through a consortium of 
institutions committed to the training program, their 
combined resources being adequate. 
Further details of training programmes can be found 
in the literature (see references 101-106).
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